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Prognostic factors in IgA nephropathy (IgAN): Ninety-seven patients
followed-up more than 10 years. M. Velo, L. Lozano, J. Egido, V.
Gutierrez-Millet, L. Hernando, Fundacion Jiménez D(az and Hosp. J
de Octubre, Madrid, Spain. IgAN is frequent in Spain; it accounts for
18% of biopsied primary glomerulonephritis and 10% of patients in
end-stage renal failure. The data from 97 patients followed for more
than 10 years after the apparent onset of IgAN, diagnosed on im-
munohistological criteria, were evaluated in search of prognostic fea-
tures. Forty-four out of 97 (45%) developed chronic renal failure (CRF)
(Group I) defined as Crs above 1.5 mg/dl. Fifty three (55%) maintained
normal renal function after 10 yrs (Group II). Mean age at apparent
onset was 22.13 10.6 yrs (range 1—48 yrs) and at renal biopsy 28.93
11.6 yrs (range 5—55 yrs). No significant differences were observed in
the ages of patients with or without CRF. Sixty-one (63%) of the
patients were males vs. 36 (37%) females. Thirty-four (97%) of the
males and 10 (23%) of the females developed CRF. Two main clinical
syndromes hallmarked the apparent onset of the disease: 1) gross
heniaturia (GH) (78%), isolated (10%) or recurrent (89%), and 2)
microscopic hematuria (mH) (12%). GH at onset was associated to:
NRF (93%), hypertension (16%), nephrotic range proteinuria (13%),
CRF (5, 3%) or acute renal failure (2%), Group II presented remission
of OH (64.4%), mH (47%) and proteinuria (47%) vs. 61% (NS), 9% (P
<0.01) and 9% (P < 0.01), respectively, in Group I. Eighty-two percent
of patients in Group I developed nephrotic range proteinuria and 95%
hypertension and hyperuricemia without diuretics vs. 17%, 37% and
55% respectively in Group II (P < 0.001). Serum IgA levels were
elevated in 64% of patients and no differences between both groups
were found. Actuarial survival (expressed as CRF and renal death)
were 38% and 19% at 10 yrs and 53% and 29% at 20 yrs, respectively.
By the last observation 55% of patients had NRF, 22% CRF, 8% had
been transplanted, 8% were on dialysis and 6% dead. Minimal changes
pattern was present in 28% of Group II (P < 0.01) vs 54.5% of diffuse
proliferative picture in Group 1 (P < 0.01). A positive correlation was
found between CRF and the presence and extent of glomerular sclero-
sis, extracapillary proliferation, synechiae, tubulointerstitial and vascu-
lar lesions and C3 mesangial deposits. In conclusion, IgAN is a
progressive disease with a not uncommon unfavorable course. Persist-
ent mH and proteinuria and hypertension are prognostic indicators of
progression to renal failure.
The role of platelet activating factor (PAF) in experimental nephrosis.
J. Egido, F. Ramirez, M.J. Rodriguez, A. Robles, A. Ort(z, C. Fierro,
F. Mampaso, C. Arriba, L. Hernando, FundaciOn Jiménez Diaz,
Centro Ramon y Cajal, Madrid, Spain. PAF can be released by
glomerular infiltrating cells and by resident cells. Therefore this phos-
pholipid could be important in renal damage. Recently we have dem-
onstrated that PAF antagonists avoid the appearance of proteinuria in
adriamycin-induced nephropathy in rats when given for 4 weeks (Eur J
Pharmacol 1987). In this work we afford new data further supporting
the role of PAF in the mediation of glomerular damage in this model,
Sprague-Dawley rats received I single dose of adriamycin 7.5 mg/kg wt
and were injected with PAF antagonists (BN 5201 or triazolobenzodi-
azepines) from day 0 (administration of adriamycin) to 4 weeks (Group
I), from day —1 to +1 (Group II). Rats receiving only adriamycin
presented heavy proteinuria (Group III). Rats of Group I had very little
or no proteinuria. Furthermore, epithelial glomerular cells presented a
normal aspect, while in rats injected with adriamycin, but not treated,
(Group III) the visceral epithelial cells showed intense degenerative
changes with effacement of the podocyte foot processes with villous
transformation and vacuoles. Rats of Group II had more proteinuria
than those of Group I, but significantly less than those of Group III. At
I and 4 weeks of adriamycin injection, the production of Tx132 and
PGE2 by the isolated glomeruli were higher than control rats (not
injected with adriamycin). There were not significant changes in the
eicosanoids production in rats treated with PAF antagonists. No
correlation between proteinuria and TxB2 and POE2 glomerular syn-
thesis was found. There was an increase in the urinary elimination of
PAF in the adriamycin rats. The in vitro incubation of normal glomeruli
with adriamycin showed important increase of PAF synthesis, with
moderate increase of TxB2. On the whole, these data suggest that PAF
can be one of the early released mediators responsible for the glomer-
ular damage in a nephropathy without cellular proliferation.
Presence of circulating antibodies against brush border antigens (FxIA)
in a patient with membranous nephropathy and bilateral pyeloureteral
stenosis. Comparison with Idiopathic membranous nephropathy. J. Gon-
zth'ez Cabrero, J. Egido, R. de Nicolas, L. Hernando, FundaciOn
Jiménez DIaz, Madrid, Spain. The glomerular lesion in autologous
immune complex nephritis in rats (Heymann nephritis) is similar to
membranous nephropathy in man. One of the immune aggregate
components is the Fx1A antigen derived from the tubular brush border.
There is a certain controversy in the literature about the presence of
circulating anti-FxIA antibodies in idiopathic membranous nephrop-
athy. In a patient with bilateral pyeloureteral stenosis with hydrone-
phrosis and membranous nephropathy, we examined the possibility that
an increase in the intratubular pressure could facilitate the passage of
the FxlA antigens to the circulation. By means of ELISA, we have
detected elevated levels ofanti-FxIA antibodies in three occasions over
the disease follow-up, By affinity chromatography, anti-Fx1A antibod-
ies were isolated from the sera, showing an inhibition percentage of
around 70% vis-h-vis 1/20 diluted anti FxlA antisera obtained from
rabbits by repeated immunizations. By contrast, in none of 8 patients
with idiopathic membranous nephropathy could the circulating anti-
Fx1A antibodies be demonstrated. This particular case suggests that
increased intratubular pressure induced by the pyeloureteral stenosis
could release Fx1A antigens, facilitating an autologous immune com-
plex nephritis. These antigens, by contrast, do not seem very important
in most of membranous nephropathy in man.
Characterization of idiotypic circulating immune complexes in patients
with IgA nephropathy. J. GonzOlez-Cabrero, R. de Nicolás, J. Egido,
Nephrology Department Fundación Jiménez DIaz, Madrid, Spain. We
have previously demonstrated that the 50% of patients with IgA
nephropathy have immune complexes (IC) with antibodies against diet
antigens and the size and serum levels of IgA-IC present fluctuations
after protein ingestion. By using anti-idiotypic antibodies obtained from
rabbits previously immunized with idiotypes anti-bovine serum albumin
(BSA) of lgG class, we have found shared idiotypes in 50% of the sera(N = 70) and 33% in polyethylenglycol (PEG)-precipitated in these
patients. In this work we have studied the levels of idiotypic antibodies
forming circulating IC detected by Raji cell assay adding heterologous
anti-idiotypes in excess. Eleven out of 32 patients studied (34%) present
IC with anti-BSA idiotypic antibodies, By sucrose density gradient
ultracentrifugation the size of these IC was in the three patients around
19S. In 7 out of 30 patients (23%) the existence of anti-BSA idiotypes
was demonstrated in the mesangial and paramesangial areas. All
together our results suggest that at least a portion of circulating IC in
patients with IgA nephropathy consists of idiotype-antiidiotype, and
furthermore they might be of pathogenetic importance,
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Adenosine induces contraction in glomeruli and rat mesangial cells. A.
Olivera, D. Rodriguez Puyol, S. Lamas, G. Arriha, J.M. Lopez Novoa,
Laboratorio de Fisiopathologia renal, Fundación Jiménez Diaz-CSIC,
Madrid, Spain. Adenosine in the kidney is able to produce decrements
in GFR and RBF through contraction of the renal vasculature. These
decrements might be related to a possible action of adenosine on the
mesangium. Thus, we studied the effects of ADO on the contraction of
rat mesangial cells (MC) in primary cultures. Mesangial cells were
incubated at room temperature with two doses of ADO (10—a and 10-i).
Measurements of apparent planar surface (APS) were performed at
different incubation times by a computerized planimetric system. After
incubation of 25 mm, ADO io— induced a reduction of 17 3% of the
APS with respect to initial values, while ADO i05 induced a reduction
of 15 3%. In addition, when MC were preincubated with verapamil or
with a calcium-free medium, no change in APS was observed. Incuba-
tion of the cells with verapamil or buffer induced no variation in APS.
In order to test a correspondence between the reduction of MC, APS
and reduction of glomerular surface area (GSA), parallel contraction
studies were performed in rat isolated glomeruli. The 20 mm incubation
of the glomeruli with ADO iO resulted in a reduction of 10% of initial
GSA (from 1.61 0.03 M2 10-8) with ADO io M. Pretreatment of the
glomeruli with verapamil or a calcium-free medium inhibited the
contraction induced by ADO. GSA did not change (1.6 0.04 to 1.59
0.04) when glomeruli were incubated only with buffer. These results
suggest that the contraction of mesangial cells may be responsible, at
least partially, for the renal effects shown by ADO. This contraction is
dependent on extracellular calcium.
Improvement of renal function in hypertensive azotemic patients after
surgical revascularization. f.M. Campistol, C.A. Mestres, A. Botey, A.
Cases, M. Guerola, S. Ninot, C. Abad, J. Mulet, L. Revert, Nephrol-
ogy and Cardiovascular Surgery, Hospital Clinic, Barcelona, Spain.
Between 1971 and 1986, 14 males and 1 female, mean age 51 yr (range
38 to 69), were seen with hypertension (HT) and renal failure. Mean
duration of HT was 57 months. Blood pressure (BP) ranged from 170 to
300/95 to 160 mm Hg, and mean BP was 163 mm Hg. Left ventricular
hypertrophy and hypertensive retinopathy were seen in all cases. The
mean preoperatory creatinine was 3.89 mg/dl (range 1.7 to 10.4), and
two patients (P) were on chronic hemodialysis (HD). Renal angiography
showed unilateral renal artery stenosis (6), bilateral stenosis (6) and
renal artery thrombosis (3). Atherosclerosis was the etiology in 13
patients, and fibromuscular dysplasia in 2. Renal autotransplantation
was performed in 3 patients, splenorenal shunt in 5, aortorenal bypass
in 5, hepatorenal bypass and bilateral renal endarterectomy in I each. In
4 patients percutaneous transluminal renal angioplasty was attempted
preoperatively. Hospital mortality was 1 case because of multisystem
failure. BP decreased in all patients. The postsurgical mean BP was 101
mm Hg (P < 0.05) and diastolic BP was less than 100 mm Hg in all
cases. Renal function improved in all patients, postsurgical mean
creatinine was 1.6 mg/dl (P < 0.05), and the two patients on HD could
left it. Follow-up ranges from 5 to 144 months. We conclude that HT
associated to renal failure must be evaluated to rule out renovascular
origin, trying to offer some type of revascularization including angio-
plasty and surgery.
ifistomorphometry of the diabetic bone after long-term treatment with
CAPD. F. Coronel, E. Hernandez, P. Naranjo, L. Hortal, C. Pozo, H.
Rico, A. Barrientos, Servicio de Nefrologia, Hospital Univeritario San
Carlos, Madrid, Spain. We have selected 10 diabetic patients main-
tained on continuous ambulatory peritoneal dialysis (CAPD) a mean of
40.2 8.6months (27—48). Seven males and 3 females with mean age of
47.5 10 yr. Duration of diabetes mellitus 22.5 8.1 yr; Ccr 8.5 2.8
mI/mm. Biochemical control was done every 2 months, bone X-ray
every 6 months, and bone biopsy (BB) in 7 patients, in relation with the
last X-ray study. We have evaluated on iliac biopsy; travecular bone
volume (TRy), resorption surface (RS), osteoide surface (OS), osteoide
volume (OV) thickness osteoide index (TOI) and aluminum stain (AS).
The control group were 8 non-diabetic patients (ND) on CAPD, =
40.8 8.8months (26—54 months), 4 M, 4 F, mean age 59 7.8 yr, Ccr
5.02 2.8 mI/mm and BR in 5 patients. Results. Lower C-PTH in D
= 1.94 vs. 7.93 ng/ml (P < 0.05). Lower alkaline phosphate (PA) and 25
(OH)D3 below normal limits 10 ng/ml in D patients. Bone X-ray: More
osteopenia and vascular calcifications and absence of subperiosteal
resorption on long term follow-up on D (P < 0.05). Histomorphometry:
Lower TBV in D normal SR in 6 out of 7 D. AS negative. Good
correlation between PTH and SR in ND (P < 0.05). There is an
increase, not significant, in OV, OS & TOl in D patients. In conclusion:
I) Histomorphometry confirms the absence of secondary hyperparathy-
roidism in diabetics with long-term evolution on CAPD, with good
correlation between C-PTH, bone radiology and bone biopsy. 2) The
low bone turnover, reduced TBV and a trend in TOI's increase with
negative aluminum stain would represent a defect in mineralization rate
in the diabetic patient. Chronic depletion in 25(OH)D3 could play a role.
Calcium carbonate as phosphate binder in hemodialyzed patients. J.
Almirall, J.M. Campistol, A. Torras, J. Lopez-Pedret, L. Revert,
Nephrology Service, Clinic Hospital, University of Barcelona, Spain.
The aim of this study has been to evaluate the efficacy and side effects
of CaCO3 as phosphate binder. We studied 22 patients in regular
dialysis treatment during a period of six months. Initially all patients
were on treatment with aluminum hydroxide (3.6 1.1 g/day) with a
main plasma calcium 9.8 0.8 mg/dl, and main phosphorus 6.1 1.9
mg/dl. Vitamin D supplementations were discontinued. Two weeks
after Al(OH)3 withdrawal all patients developed hyperphosphatemia
(8.65 1.86 mg/dl). CaCO3 was then started in all of them, doses being
increased to maintain pre-dialysis plasma phosphorus below 5.5 mg/dl,
and plasma calcium between 9.5—li mg/dl. Diet was not changed.
Calcium concentration of the dialysate was decreased to 6 mg/dl, and
aluminum content was less than 2 pg/liter. After six months of follow up
with CaCO3 alone as phosphate binder 14 patients (64%) remained
stable, with a good control of serum phosphorus (5.2 1.5 mg/dl). The
mean dose of CaCO1 was 7.3 g/d (range 4—12 g/d), and mean plasma
calcium 10.1 mgldl (range 8.1—11.4 mg/dl). Aluminemia fell significantly
after the introduction of an aluminum-free regimen with CaCO3 from
106 to 41 tg/liter (P < 0.001). In two patients aluminum hydroxide had
to be added to control hyperphosphatemia and avoid hypercalcemia.
Four dropped out because of moderate diarrhoea and/or dislike of the
treatment. Two patients were excluded because of hypercalcemia and
severe hyperphosphatemia. Conclusions: I) CaCO3 was effective to
control hyperphosphatemia in 14 of 22 patients (64%) with a main dose
of 7.3 g/day (range 4—12 g/day). 2) We have little side effects, digestive
intolerance has dropped out four patients. 3) Four patients presented
hypercalcemia, two of them need to be dropped out. 4) Serum alumi-
num concentration fell significantly after introduction of an aluminum-
free regimen.
Facts we should take into account if we aim to reduce the risk from oral
aluminium in hemodialysis patients. J.B. Cannata, f. Lamas, M. Ser-
rano, J.L.F. dez Martin, A. Sanz Medel, Hospital General de Asturias,
Universidad de Oviedo, Spain. During the last decade aluminium (Al)
toxicity has emerged as one of the most serious complications arising
from the treatment of chronic renal failure. The aim of these studies was
to reduce the oral aluminium exposure in renal patients (pts) by means
of; A): (STUDY A) investigating the short-term effect of introducing 1
(25) vitamin (vit) D3 on serum P and Al levels and B): (STUDY B)
studying other less known sources of oral Al exposure related with the
daily cooking. STUDY A: As in a previous retrospective study we
found results suggesting that 1 (25) vit could increase serum P; in this
study we prospectively evaluated the short-term effect (1 month) of
introducing (without modifying the P binders) a low dose (0.25 pg/day)
of 1,25 vit D3 on serum P levels in 20 pts who never received the drug.
We found a significant (P < 0.001) serum P increase (from 1.54 .03 to
1.99 .05 mmollliter). There were no significant changes in serum Al
levels. STUDY B: We investigated the Al released by different cooking
utensils such as pans, (enamel, earthenware and Al made) and the Al
kitchen foil. After boiling during 15 to 45 minutes a low-Al solution
(samples were taken at 0, 15, 30 and 45 minutes and Al was measured)
all cooking utensils studied released Al, particularly the Al kitchen foil,
which after 45 minutes of cooking (using low-Al but acid solutions,
similar to any current cooking pH) was able to release 12000 to 14000
mg/liter of Al [the equivalent to 50 to 70 (475 mg Al(OH)3) tablets]. The
present studies give convincing evidence that 1,25 vit D3 introduction
might impair serum P control, making necessary to increase the P
binders, and it also draws the attention to other not yet studied but
current sources of oral Al exposure in renal pts, helping us to minimize
the risk of Al toxicity.
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Aluminium gastrointestinal absorption: Experimental studies. M.J.
Fdez-Menendez, J.B. Cannata, 1. Fdez-Soto, M.J. Virgos, J.L. Fdez
Martin, Hospital General de Asturias, Universidad de Oviedo, Spain.
Previous studies found difficult to set up suitable clinical and experi-
mental tests to study 0-I Al(OH)3 absorption and the likely factors
influencing it. Therefore, the aim of this study was: 1.) to evaluate
different models and factors involving the Al(OH)3 absorption in order
to found a suitable method to be used as Al absorption test in clinical
practice; 2.) to study different areas of Al absorption investigating
different segments of gastrointestinal tract by means of using two
external ligatures. We studied 75 adult Wistar female rats (weight: 200
to 250 g). In vivo studies: (N = 40, in metabolic cages). We studied
serum and urinary Al changes within the first 24 hrs following a known
load of Al(OH)3 (from 20 to 240 mg, administered using gastroesophagic
catheter), studying also other factors likely able to modify absorption,
such as G-I pH variations, renal failure, chronic aluminum toxicity (oral
and intraperitoneal), and fluor administration. We investigated the Al
absorption with and without stomach and duodenum clamping, aiming
to individualize the Al absorption from both segments. In vitro: (2
phases). We studied the stomach and duodenum separately analyzing
the Al transfer from the isolated segments to an Al-free bath during 3
brs of follow-up. The "in vivo" results showed that urinary results were
more accurate than serum results, which have important individual
variations. We obtained the urinary Al peak level more than 12 hrs after
the oral Al(OH)3 load and the serum Al peak level within 3 and 6 hrs
after the Al(OH)3 exposure. We found aluminium absorption from the
isolated stomach and duodenum segments although we did not find
significant differences between them (peak levels: serum 200 to 300%,
urinary from 500 to 900%). Only the fluor diminished in the aluminium
absorption. Urinary Al increments following 24 hrs Al(OH)3 load: fluor,
from 1610 to 4100; CRF, from 1118 to 9850; chronic Al toxicity, from
6490 to 8160 ng A1124 hrs. The in vitro studies also showed Al transfer
from the 0-I segment to the bath, being the peak level 3 hrs following
the Al(OH)3 load. These experimental studies prove that the Al is
absorbed from the stomach and duodenum. Serum samples have
serious limitations, so the urinary samples appear as necessary for
studying Al(OH)3 absorption and its modulation. Moreover, the previ-
ous chronic aluminium toxicity did not diminish significantly aluminium
absorption, so it seems there is no evidence of specific negative
feedback mechanism for Al 0-I absorption.
Parathyroid gland functIon and aluminium concentration in rats with
renal insufficIency. J.B. DIaz-Ldpez, P. D'Haese, E,J. Nouewen, F.
Arroyo, J.B. Cannata, M.E. De Broe, Hospital General de Asturias,
Oviedo, Spain, and University of Antwerp, Belgium. It is well known
that aluminium (Al) could suppress the parathyroid gland (PTG). The
aim of this cooperative study was to evaluate the influence of chronic Al
load on PTG response and PTG Al. We studied 31 male Wistar rats
divided into three groups: Group I, normal control rats; Group II,
uremic control rats; Group III, uremic rats Al-loaded with intraperito-
neal administration of elemental Al I mg/day for 44 days. The renal
failure in Groups II and III was obtained using the remnant kidney
model. Rats Al-loaded to cause renal failure showed a significantly
lower PTH value (25 6 pg/mi) than Al-non-loaded rats (70 32, P C
0.01) and controls (32 8). There were no differences in serum Ca
among the three groups. Moreover, the PTG-Al content was signifi-
cantly higher in the Al-loaded rats compared with the non-loaded,
together with also higher Al-concentrations in serum, bone and liver. In
addition, a complementary and consecutive study done in uremic,
chronically Al-loaded rats, have shown neither decrease in PTG-Al
concentration nor increase in PTH serum levels after using desfer-
rioxamine during 5 weeks. In summary: in chronic Al-intoxicated
animals with renal failure we observed a reduced serum PTFI level and
a significant increase of PTG-Al content, suggesting a direct inhibitory
effect of Al on PTH secretion, which according to the morphological
changes observed [marked hyperplasia, (P C 0.01)1, seems to be
secondary to a decrease in PTH release, rather than to a reduced P'FH
synthesis.
Myocardial function during hemodlalysis: Experhnental re-evaluation
of the effect of the ailtalinlzing agent used in the dialysate. M. .Jaraba,
M.J. Requena, D. Castillo, R. Guerrero, A. Martin-Malo, J, Mallol,
F.M. Gonzalez, P. AIjaina, Hospital Reina Sofia, Cordoba, Spain. The
effect of hemodialysis (HD) with dialysate containing acetate (Ac) and
bicarbonate (Bi) on peripheral hemodynamics and cardiac performance
was assessed in two groups of 7 uremic mongrel dogs (bilateral ureteral
tie), excluding additional circumstances which determine cardiovascu-
lar instability during HD: isovolemia (ultrafiltration monitor), isona-
tremia and isocalcemia (adjusted dialysate), isothermia (thermistor) and
absence of hypoxemia (mechanical ventilation). Every 15 mm until 90
mm the following parameters were measured: mean arterial pressure
(MAP), peripheral vascular resistance (PVR), cardiac output (CO) and
stroke index (thermodilution), left ventricular stroke work index
(LSWI), acetate blood levels (ABL) and plasma volume (PV) (albumin
1-131).
Main results:
15mm 90mm
Ac Bi Ac Bi
MAP %
PVR%
CO%
LSWI%
ABL mEqiliter
PVliter
—3
25*
4.8*
1.6
—1
0
0
0.2
1.8
6.7*
1.5
7
+2
4I1
0.2
1.9
Ac determines a significant depression in left ventricular contractility
which is documented by a significant decrease in LSWI. In addition Ac
produces a fall in PVR manifested by arterial hypotension. In contrast
Bi maintains myocardial function as well as peripheral vascular hemo-
dynamics.
Pulmonary hypertension and gas exchange alterations during hemodl-
alysis. Are they related? D. Castillo, R. Guerrero, A. Escassi, M.
Jaraba, A. Salvatierra, A. Martin-Malo, P. AIjama, Hospital Regional
"Reina Sofia", Cordoba, Spain. Previous studies have demonstrated
that HD with cuprophane (CU) membrane produces pulmonary hyper-
tension (PH). This phenomenon is apparently related with pulmonary
functional changes such as arterial oxygen tension (Pa02) fall and
intrapulmonary shunting (QS/QT) increase. However, gas exchange
studies suggest that modifications of the pulmonary diffusing capacity
could also play a relevant role in the Pa02 decrease. The aim of this
work was to study the alveolar gas exchange with different membranes
during the HD and its relationship with the pulmonary hypertension.
The studies were performed in 27 normal dogs, during a 60 minutes HD,
under mechanical ventilation (no hypoventilation), and Fi 02 50% (gas
exchange studies). Eleven animals were dialyzed with CU membrane, 9
with polyacrylonitrile membrane and 7 with CU membrane receiving
the animals of this group a prostaglandin E1 (POE1) constant infusion
(0.2 mg/kg/mm) to avoid the pulmonary hypertension triggered by CU.
The following parameters were studied, at 0, 3, 5, 7, 10, 15, 30 and 60
minutes: PaO2, mixed venous oxygen tension, mean pulmonary arterial
pressure (PAP), (Swan-Ganz), QS/QT, alveolo-arterial gradient (DA-
aO2), pulmonary vascular resistances (PVR), cardiac output and 02
consumption (VO2).
Main results at 15 mm. A%:
CU CU + PGEI AN69
PAP +10.7* +5.2 +3.7
PYR +62.& +25.9* +26.1
PAO2 21,7b
DAaO2 +77.6c +51.5* +48.5*
QS/QT +52.9* ÷36.sa +28.2
V02 +1.1 —2.5 +14.2
p c o.s, P C 0.01, P C 0.001
Cuprophane membrane HD produces pulmonary hypertension, associ-
ated with QS/QT and DA-aO2 increases which together will promote a
decrease in Pa02. PGE1 avoids PH induced by CU membrane. PH and
gas exchange damage during HD are unrelated phenomena.
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Paired filtration dialysis (PED), a new hemodiajiltration technique
ready to become a routine practice. J. Botella, P.M. Ghezzi, R.
Vanholder, A. Santoro, C. Sanz Moreno, P. Zucchelli, S. Ringoir,
Dept. Nephrology of Madrid, Spain, Cuneo and Bologna, Italy, and
Gent, Belgium. PFD is a new hemodiafiltration technique using a filter
with two online but independent chambers. The first is a hemofilter
where hemofiltmtion is carried out, with a total equivalent volume of
10% of body weight; the second is a dialyzer and diffusion is carried out
in it. The technique was analyzed using classical parameters (BUN, Cr,
P, uric acid, Vit B12) and the HPLC method (hippuric acid, unidentified
peaks 4 and 5 and the total UV-absorbing substances). Using the results
the clearances and the mass flux of the whole system, the hemofilter and
the dialyzer were calculated. The hemofilter increases the clearance of
the system by 24.58 16.35% and the mass flux by 24.62 4.96%,
which allows a 25% reduction in blood purification time, from 240 mm
to 180 mm, 3 times per week and blood flux 291 15 mI/mm. With these
figures the following results were obtained: Short-term data: There
were no significant changes in the extraction of the substances analyzed
(BUN, Cr, hippuric ac., peaks 4 and 5, total UV-Abs.) nor in the NCDS
parameters (midweek BUN 86 15, TAC 57 12, Kt/V 0.99 0.1,
PCR 1.2 0.1), N = 8. The serum beta-2-microglobulin levels reduced
after 3 months treatment, 43.79 22.47 vs. 32.71 14,04 (P < 0.05), N
= 11. Long-term data: Over 12 months 21 patients were transferred
from HD (12 hr/week) to PFD (9 hr/week); good intra- and interdialysis
tolerance was obtained and there were no statistically significant
changes in the clinical and biochemical parameters.
Effect of bicarbonate (BIC) and acetate (ACE) dialysate of 3 or 4 hours
hemodialysis (LID) on colloid osmotic pressure (COP). A. Franco, R.
Perez-Garcia, J. Luño, E. Junco, R. Robles, F. Valderrabano, Servicio
de Nefrologia, Hospital General "Gregorio Maranon", Madrid, Spain.
Ultrafiltration (UF) associated to diffusion may produce hypovolemia
and hypotension. The degree of hypovolemia is determined by the
rapidity of fluid removal and the vascular refilling rate. The vascular
refilling rate is related to the value of COP and this is a major factor to
evaluate plasma volume change. We have studied, in ten patients, the
effect of 5 schedules of dialysis on COP, plasma volume change and
vascular instability in order to evaluate a possible different effect of
ACE and BIC buffers on extravascular fluid mobilization to explain a
different hemodynamic stability during HD. Dialysis schedules were:
I.) HD; 3 hours (Hr); dialyzer, 1.4 m2 cuprophan 8 dialysate, ACE
35, Ca 3.5, Na 138 mEq/liter, Osm 294 mOsm/kg. 2.) I-ID; 1 except to
BIC 39 mEq/liter instead of ACE. 3.) HD; 4 hr; 1.3 m2 cuprophan II
dialysate = 1 (ACE). 4.) HD; 4 hr; 1.3 m2 cuprophan 11 s; dialysate =
2 (BIC). 5.) Hemodiafiltration (HDF); 3 hr; dialyzer 1.2 m2 PAN;
dialysate, ACE 35, Ca 3.25, Na 134 mEq/liter, Osm 293 mOsm/kg;
substitution fluid 3 liter, Na 145 BIC 100 mEq/liter. All dialysis sessions
were performed in volumetric controlled UF machines (Monitral R)
Basal COP, 23.6 to 26.2 mm Hg, increased during HD or HDF session
in relation to volume UF, i 20 to 40%/l.9 to 2.5 1. UF. P < 0.01,
without any differences between ACE versus BIC HD, 3 or 4 hr, nor
HDF, although vascular instability was less during BIC HD. A corre-
lation (P < 0.001) was found between plasma volume decrease,
calculated from hematocrit change, and COP, similar with ACE and
BIC. (N = 20; r = 0.95; y = 1.64 X + 5.25). Improved hemodynamic
stability utilizing BIC may be not due to a greater plasma refilling and
better preservation of plasma volume. (HD 3 or 4 hr; dialysate: Na 138
mEq/liter).
Evaluation of different dialysis schedules to reduce dialysis time. J.
Luño, A. Fraco, R. Perez, F. Valderrabano, A. Alvarez de Lara, S.G.
de Vinuesa, S. Alonso, Hospital General G. Maranon, Madrid, Spain.
Based on urca kinetic modeling, 38 chronic dialysis patients previously
treated with conventional hemodialysis 12 to 15 hours/week during a
mean period of 56 35 months, were transferred to 3 different dialysis
schedules. The aim was to get adequate dialysis in shorter treatment
time. A diet that provided Ito 1.4 g/kg/day was prescribed in all cases
trying to maintain a TAC value <60 mg/dI. Blood flow was increased to
350 mI/mm. 1.) Hemodialysis 3 hours/3 times a week with a cuprophan
dialyzer of 5 s and 1 m2 or 8 .s and 1.4 m2 (buffer:acetate): 9 patients.
2.) Hemodialysis 3 hours/3 times a week with the same dialyzers and
bicarbonate as dialysis buffer, 13 patients. 3.) Hemodiafiltration with
infusion of 3 liters of a bicarbonate fluid 3 hours/3 times a week and a
dialyzer of AN-69, 1.2 m2 (BF): 16 patients. The mean time of follow-up
was: 14 6 months (8 to 37 months). No significant differences were
observed in mid-week predialysis biochemical data during the shorl
dialysis period, including: urea, Cr, uric, phosphate, Hb, reticulocytes,
potassium, transferrmn, ferritin, Vit B12, folic acid, albumin and lipids.
Total calcium decrease significantly in BF. But there were not any
significant differences in PTH and alkaline phosphatase values. BF and
bicarbonate hemodialysis improve significantly the correction of acido-
sis. During the short dialysis period there were not differences in
clinical situation of the patients and the nerve conduction velocity and
cardio-thoracic index were similar. The best dialysis tolerance was
obtained with bicarbonate hemodialysis. But there were not differences
in frequency of dialysis symptoms with the short dialysis schedules,
neither in pre- or post-dialysis mean arterial pressure or in post-dialysis
weight. In conclusion our data confirm that urea kinetics modeling is
safe and useful in monitoring dialysis and nutritional therapy. Increas-
ing the efficacy of dialysis may permit obtain adequate dialysis in at
least 25% shorter time with the same tolerance, permitting better
rehabilitation of the patients and reduction of costs.
Platelet function in end-stage renal disease (ESRD). A. Perez, M.
Sanchez, M. Linares, A. Cerveró, f.M. Escobedo, L. Garcés, J.
Villaro, R. Moll, J. Sanchis, Hematology and Nephrology Depart-
ments, Valencia General Hospital, Valencia, Spain, The effect of
hemodialysis (I-ID) on platelet function is studied in 13 ESRD patients
who had not been previously dialyzed and were free of hemorrhagic
diathesis. Platelet function tests were determined before and one hour
after patient's first HD in each case. All patients were dialyzed with
cuprophan membrane dialyzers, for four hours. The control (CG) group
was composed by healthy individuals. Statistical analysis was per-
formed with the t-test for paired data. Platelet aggregation induced by
ADP, arachidonic acid, ionoforo A-23187, ristocetin and collagen, and
ATP release induced by collagen were normal, compared with CG.
There were no differences between pre-HD and post-HD data. FVIII
complex levels were normal or slightly high, there being no changes
after HD. Platelet adhesiveness was impaired in ESRD patients,
improving after HD (P < 0.01). In the same way, malonil dialdehide
acid (MDA) release induced by arachidonic acid was impaired (10.8
4.8 M/l09 platelets) with respect to CG (19.8 4.9, P < 0.002), and it
increased significantly after HD (14.8 3.6, P < 0.004). Serum
thromboxane B2 (TxB2) pre-HD levels were in the low limit of normal
range (146 31.9 ng/ml), there being no difference with CG (126.5
17.6), but they decreased significantly after HD (64.9 45.5, P <
0.001). This fact had not been previously reported. Because of disparity
between the increase in MDA and the decrease in serum TxB2 after
HD, discussion is centered in the reliability of this parameter for the
evaluation of platelet function and the changes induced by HD in
patients with ESRD.
Exercise capacity and metabolic effects in end-stage renal disease. X.M.
Lens, P. Codinach, R. Pascual, P. Franco, J. Carrio, J.A. Oliva, J.M.
Mallafre, Nephrology and Cardiology Services of Hospital de Ia Cruz
Roja of Barcelona, Spain. Vigorous exercise induces in healthy volun-
teers an elevation in serum potassium of around I mmol/liter, modu-
lated by adrenergic receptors (N Engi J Med 312:823—7, 1985). This
increment would be specially dangerous in patients with renal failure
because of their known tendency to hyperkalemia. We therefore
investigated the effects of bicycle exercise to exhaustion in 12 patients
with end-stage renal disease, 10 on hemodialysis and 2 on chronic
ambulatory peritoneal dialysis. Mean serum creatinine was 11 2
mg/dl, mean age was 44 12 years and mean hematocrit was 28 6%.
The test was performed on an electronically braked ergometer while
attached to a cardiac monitor, each workload was performed for 2 mm
and was increased in 25W. The duration of exercise was 10 2 minutes
and exercise work was 3.304 1583 kpm, significantly lower than 8.100
1.200 kpm in healthy volunteers in our laboratory, P < 0.01. When
basal serum potassium levels were compared to the serum potassium
levels at the end of exercise, they did not differ significantly (5.2 + 0.6
vs. 5.5 0.6 mmol/liter, P = NS), although exercise induced a decrease
in venous pH (7.33 0.05 vs. 7.23 0.08, P < 0.01) and plasma
bicarbonate (19 3 vs. 14 4 mmol/liter, P < 0.001). In addition
exercise induced an important increment, P < 0.01, in mean arterial
pressure (97 19 vs. 136 17mm Hg), heart rate (83 3 vs. 139 24
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ppm), serum sodium (141 3 vs. 143 4 mmol/liter), plasma norepi-
nephrine (454 253 vs. 4382 267 pg/ml) and plasma epinephrine (90
47 vs. 418 491 pg/ml). End-stage renal disease is accompanied with
a decrease in exercise capacity. Patients with renal failure can perform
exercise with moderation because, although exercise induces a slight
worsening of metabolic acidosis, serum potassium levels do not change
significantly.
Clinical presentation and prognostic factors in adult hemolytic-uremic
syndrome (IJUS). M. Perez-Fontan, E. V. Martul, J. Oliver, M. Adeva
and F. Valdes, Hospital Juan Canalejo, A Coruna, Spain. We analyze
clinical presentation, evolution and prognostic factors in patients who,
since 1974 to 1987, presented a clinical and histological syndrome
consistent with HUS-thrombotic microangiopathy (TMA). We ex-
cluded patients under 10 years of age, those with well-defined previous
arterial hypertension (HT), and cases of HUS-TMA in a discrete
context (renal transplant rejection, progressive systemic sclerosis,
etc.). We studied 18 patients (10 males), 35 20 years-old (10 to 85).
Two patients were brothers, and developed HUS with an interval of five
years. Three cases followed pregnancy (3 days to 8 months), two were
preceded by recent surgery, and one patient was under oral contracep-
tion. Only ten patients presented a definite prodrome (digestive in five
cases, respiratory in four, parotiditis in one). The most frequent
presenting symptom was nausea and vomiting (39%), being abdominal
pain, asthenia, leg edema, dark urine, and oliguria the presenting
manifestation in 22% each. Oliguria or the detection of renal insuffi-
ciency were the main reasons for hospital admission. In the whole
evolution, the clinical syndrome was dominated by general (asthenia
100%, vomiting 44%), renal (oliguria 72%, macrohematuria 39%),
neurologic (cephalea 61%, low level of consciousness 44%, convulsive
crises 33%), hemorrhagic (cutaneous 33%, other 33%) and cardiovas-
cular (heart failure 50%, peripheral edema 55%) events. Ten patients
were in anuria, and three in oliguna, for variable periods of time; only
five conserved diuresis. Four (23%) fulfilled clinical criteria for the
diagnosis of malignant HT (mHT) at admission, and in other four cases
HT evolved to a malignant phase or developed as such de novo after
admission. All patients showed clear signs of microangiopathic hemo-
lytic anemia (MHA), which were severe in 67%. Eight patients pre-
sented hepatomegaly. The treatment regimes along a 13 year period
were very heterogeneous, and consequently difficult to analyze, Five
patients died precociously (3 to 105 days after admission), and two
other after 49 and 58 months in dialysis (HD). Four patients entered a
HD program precociously (2) or late in their evolution (2); two of them
received a renal allograft, without recurrence of HUS. Only four
patients recovered renal function ad integrum. Mean follow-up was 35
40 months (2 to 140), excluding early deaths. Prognostic factors in the
short term (early death) were: anuna, neurologic events persisting
beyond 48 hours after admission, severe MHA and age over 40 years;
mHT, hemorrhagic events or heart failure were less determinant.
Long-term prognosis (renal function) correlated with mHT and severe
MHA in the acute phase; anuna (even prolonged) was not a consistent
prognostic feature.
Renal involvement In scleroderma: Relationship with capillary pat-
terns. A. Cases, H. Knobel, X. Sobrino, E. Kanterewicz, C. Herrero,
M. Vilardell, L. Revert, Nephrology and Internal Medicine Services of
Hospital Clinico and Internal Medicine Service of Residencia de la Vail
d'Hebró, Barcelona, Spain. Renal involvement in scleroderma (SCL),
defined by the presence of hypertension (HT), proteinuria and/or
azotemia is an index of poor prognosis in the course of this disease.
Capillaroscopy is an easy and bloodless method recently introduced in
the study of SCL. The aim of this protocol was to study whether renal
involvement in SCL is associated with a definite capillary pattern which
may allow its early detection. Forty-four patients with SCL (27 patients
with progressive systemic sclerosis and 17 with CREST syndrome)
were studied: 5 males and 39 females. Mean age: 52 years (range 19 to
77 years). Mean time of evolution of SCL: 9 years (range 6 months to 26
years). Seven of 44 patients (16%) showed HT and 4 of these 7 patients
also had other signs of renal dysfunction: 3/7 presented a scleroderma
renal crisis and 1/7 had HT plus proteinuria. 15/44 patients (34%)
showed an active capillary pattern, while the rest showed a slow or
intermediate pattern. The active pattern was more frequent among
patients with HT (5/7; P < 0.05) and constant (4/4) in patients with HT
plus azotemia or proteinuria (P < 0.02). In order to study the possible
role of HT in the capillary pattern capillaroscopy was also performed to
15 control patients with essential HT (2 with malignant HT) but
disclosed minor and nonspecific capillaroscopic abnormalities. Renal
involvement in SCL is frequently associated with an active capil-
laroscopic pattern. Capillaroscopy might be an easy and useful tool to
predict the appearance of renal involvement in patients with SCL,
although further prospective studies are needed to confirm this hypoth-
esis.
Increased proximal sodium reabsorption in liver cirrhosis. J. DIez, F.
AntOn, F,J. Indart, A. Purroy, J. Prieto, Dept. of Medicine, University
Clinic, Pamplona, Spain. The tubular hyperreabsorption of Na4 is a
frequent complication of cirrhosis whose origin is not well known. In
this paper we have investigated the proximal reabsorption of Na4 in
cirrhotics with normal creatinine clearance. To do this, we studied the
renal lithium (Li) clearance, an index of proximal tubular reabsorption
through the Na4:H exchanger of the luminal membrane, and the
activity of erythrocyte Na(Li4):H4 countertransport, evaluated
through the rate constant for Li4-stimulated Na4 effiux in fresh
erythrocytes. The study was realized in 19 control healthy subjects
(group I), II cirrhotics without ascites (group 2) and 29 cirrhotics with
ascites not treated pharmacologically (group 3). All studies were done 4
days after taking a diet of 40 mmol/clay of Nat The group 2 patients had
lesser fractional clearance of Li4 (10.33 2.14%, P < 0.05) and higher
erythrocyte countertransport activity (0.023 0.001 x hC', P < 0.001)
than the group I control (19.05 2.67% and 0.014 0.005 x hr',
respectively). With respect to group 1, the group 3 patients presented
lesser Li clearance (7.93 1.18%, P <0.001) and higher erythrocyte
countertransport activity (0.022 0.001 X hr', P <0.001). There was
no difference in the parameters between the two groups of patients. The
activity of erythrocyte countertransport was inversely related to Li4
clearance (r =
—0.55, P < 0.001) when the results of both parameters
obtained in the three groups of subjects studied were combined. These
results suggest that the proximal Na reabsorption is increased in
cirrhotics with a diet poor in Na4 and that the erythrocyte Na
(Li+):H+ countertransport could be a marker of renal abnormality.
Metabolic effects of valproic acid on isolated rat renal cortical tubules.
M. Rengel, M. Doval, J.M. Lopez-Novoa, FundaciOn Jiménez Diaz—
CSIC, Madrid, Spain. Vaiproic acid (VPA), or dipropylacetic acid, is
an antiepileptic agent known to produce hyperammonemia in humans.
A VPA-induced hyperammonemia may result from several mecha-
nisms, including an accelerated renal glutamine uptake and ammonia
production. In this context the effect of VPA (0.1, 1 and 10 mM) was
studied on a suspension (N = 6) of renal proximal cortical tubules
obtained from rats in normal acid-base balance. When the tubules were
incubated with 1 mri glutamine the addition of 1 mr't VPA accelerated
the glutamine uptake from 40 to 61 mol/hr/g wet wt and ammonia
production from 81 to 128 mol/hr/g wet wt (P < 0.05). When 10 mM
VPA was added, this effect was higher and a lactate and pyruvate
accumulation was observed. With 5 mri glutamine a rise in glutamine
uptake and ammonia production were observed. With lactate 1 or 5 m,
lactate and pyruvate utilization and gluconeogenesis were drastically
reduced with increasing concentration of VPA. Glutamate, malate,
alanine and aspartate production were not changed significantly by
VPA. In summary, VPA interferes with pyruvate and lactate metabo-
lism and increases glutamine uptake and ammonia production.
Partial purification of a renal DNA synthesis stimulating factor from
plasma of uninephrectomized rats. F. Manzano, P. Esbrit, F. de Miguel,
C. Castilla, Laboratorio de la Unidad Metabólica and Cirugla Exper-
imental, Fundación Jiménez DIaz (associated with the C.S.I.C.),
Madrid, Spain. Several in vitro and in vivo studies have suggested the
existence of a humoral regulator(s) of compensatory renal growth after
uninephrectomy (UNX). However, the source and the chemical nature
of this regulator remain unknown. In the present studies, a protein
fraction was separated from plasma of rats obtained 24 hr after UNX.
This fraction, injected in mice, increased the incorporation of
(3H)thymidine (0.5 p.Ci/g body wt) into renal DNA. Plasma (30 ml)
obtained from female Sprague-Dawley rats (200 to 300 g body wt) after
UNX or sham operation (5), was first chromatographed on an Ultrogel
AcA 54 column (2.5 x 90 cm) in 50 mM sodium phosphate (pH 7.4), at
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an upward flow rate of 30 ml/hr, at 4°C. Column eluents were pooled in
different fractions, lyophilized and concentrated before testing for
mitogenic activity (expressed as incorporated dpm/mg renal DNA). The
fraction corresponding to 17 k to 22 k of molecular weight from UNX
plasma, showed activity which was dose-dependent, reaching a maxi-
mum of 50% over that of S with 30 g protein (14 x l0—% of original
plasma). This active fraction was then further purified by ion-exchange
HPLC. Mitogenic activity was excluded from a Mono S HR 5/5 column
(Pharmacia) but it was adsorbed into a Mono Q HR 5/5 column
(Pharmacia), eluting at 0.2 M NaCl in 20 msi Tris-HCI (pH 7.5). The
mitogenic activity of this purified fraction peaks at 2 g protein (10—%
of original plasma). Recovery of mitogenic activity at this step was
>80%. The presence of this activity in rat plasma after UNX supports
the existence of a specific renal growth factor or renotropin.
PAF-acether receptor inhibition by BN-52021 protects against acute
renal failure. A. López-Farré, P. Perez Rodrigo, M. Torra/bo, P.
Braquet, J.M. López-Novoa, FundaciOn Jiménez DIaz, CSIC, Madrid,
Spain. PAF-acether is an alkyl phosphoglyceride released by the kidney
that when infused in the renal artery causes decreases in glomerular
filtration and renal plasma flow. To analyze whether PAF-acether could
play any role in the pathogenesis of glycerol-induced acute renal failure
(ARF; 50% glycerol in water, 10 mI/kg i.m.) in rats, the effect of
PAF-acether receptor inhibition by BN-5202l in ARF was studied. So,
BN-52021 was injected 1 mg/kg i.p. at the same time of ARF induction,
and the evolution of renal function evaluated in the 3 first hours and 3
days after ARF by clearance techniques and with metabolic cages,
respectively. The control group received the BN vehicle (40% dimethyl
sulfoxide in saline, i.p.) in addition to glycerol. In this group after ARF,
glomerular filtration decreased (0.26 0.098 mI/mm, mean SEM) in
comparison with the BN group (1.22 0.26 mI/mm) and renal plasma
flow (control group: 0.76 0.29 ml/min, BN group: 3.91 1.08 mI/mm).
Similar results were obtained with studies in metabolic cages. There
were no histological or lipid peroxidation differences between treated
and untreated animals. We conclude that a single injection of BN-5202l
protects against ARF. These results suggest that PAF-acether plays a
role in the pathophysiology of glycerol-induced ARF, at least in its first
stages.
The effect of cyclosporin A (CyA) on mesangial cell contraction: A
possible mechanism of nephrotoxicity. S. Lamas, D. RodrIguez-Puyol,
A. Olivera, G. de Arriba, J.M. Lopez Novoa, Fundación Jiménez
DIaz-CSIC, Madrid, Spain. CyA induces with some frequence acute
and reversible decrements of glomerular filtration in patients receiving
treatment with this drug. The pathogenesis of this effect is not yet well
known. In order to study if CyA could modify glomerular filtration
through reduction of ultrafiltration surface we studied its effect on
primary cultures of rat mesangial cells. Cells were exposed to CyA at
concentrations between 10—6 and lO M and microphotographs taken
at different times (0, 8, 15, 30, 60 mm) and cell apparent planar surface
(APS) was measured with a computerized planimeter. Preincubation
with lysin acetyl valycilate (LAS) l0 M, BN-52021 (which inhibits the
union of PAF to its receptor) 5 x l0- M or verapamil lO M was also
evaluated. Concentrations of CyA between 10—6 and lO induced
significant reduction of APS with respect to control-ethanol 0.0 1%, P <
0.01. Preincubation with BN-52021 totally inhibited this effect. LAS or
verapamil prevented CyA induced reduction only partially. These
results allow us to conclude that CyA induces mesangial cell contrac-
tion, thus supporting the hypothesis of reduction of ultrafiltration
surface as the mechanism responsible for decrements of glomerular
filtration induced by CyA. This contraction could be mediated by
release of PAF and eicosonaids which could act by increasing the flow
of calcium into the cell.
Effect of cyclosporine (CyA) on tubular acidification. J. Ba/larin, R.
So/a, E. Gagliardi, C. Yañez, R. Daponte, I. Donate, R. Vim, R.
Castellet, G. del RIo, Fundacion Puigvert, Barcelona, Spain. We have
studied the distal tubular acidification in 8 patients who underwent renal
transplantation before (Ia) and after (Ib) the CyA suppression, and in 9
patients treated with azathioprine (II). The study has been performed in
Ia at 5, 3 1.4 months after transplantation, in lb at 6, 1 1.6 months
after suppression, and in II at 5.9 1.8 months after renal transplan-
tation. Tubular acidification was studied by determination of PG2 in
alkaline urine, by sodium sulphate infusion and EFK by sodium
sulphate infusion and acetazolamide administration. Results. Under
basal conditions, the acid-base balance, plasmatic K, and urinary pH
were similar in the three instances.
Ccr ml/
mm
Bicarbonate
EF HCO3 pCO2
N
pH
a2SO4
EFK
Aceta-
zol.
EFK
Aldoster-
one urine
nmol/24 hr
Ia m 77.6* 5.1 60.8* 5.1 20.7* 23.2* 40.3
DS 14.4 2.6 0.7 0.4 7.6 5.5 25.7
lb m 93.2* 6.5 67,1 5.2 22.9 24.8 69.8*
DS 9.6 2.3 6.1 0.4 8.2 2.7 41.8
II m 88.4 7.3 80.7* 5.2 37,7* 31.7* 46.2
DS 12.3 2.7 13.1 0.5 15.5 5.9 26.4
P <0.05 NS <0.05 NS <0.05 <0.05 NS
Conclusions. In the patients treated with CyA a tubular abnormality
evidenced by a diminishing of the H secretion (lower pCO2 in alkaline
urine) and EFK when stimulated with Na2 SO4 and acetozolamide are
observed. This disturbance is not related with hyperaldosteronism.
After the CyA suspension, an improvement of the renal function and an
only partial correction of the H and K secretion is observed. CyA is
one of the drugs that can influence the distal tubular function.
Usefulness of duplex-Doppler (DII) in the diagnosis of renal transplant
(RT) complications. M. Cabello, M. Gonzalez-Mo/ma, G. Alvarez. M.A.
Frutos, P. Aranda, E. Lopez de Novales, Hospital Regional de
Má/aga, Servicio de NefrologIa, Malaga, Spain. The new technique of
pulsed and continuous Doppler facilitates the measurement of several
different levels of renal blood flow. To evaluate its usefulness in RT
diagnosis, a series of 98 DD studies were carried out on 47 renal
transplant patients using the same protocol to obtain the curves for
renal arteries (RAs), segmentary arteries (SA5), and arcuate arteries
(AA5). The systole-diastole relationship is quantified by a pulsatility
index (P1) computed automatically from the area of the curves: systolic
area — diastolic area/mean. Three groups of patients were used. The
first comprised 24 patients (39 13.1 years) with normal renal function
(creatinine 1.1 0.35 rng/dl), who served as controls. Characteristi-
cally, their curves presented a systolic peak followed by a gradual
diastolic decline. The second contained 17 patients (33.4 9.5) with
acute rejection (AR); confirmed histologically in 10 (58.8%). Statistical
comparison of the P1 in the two groups revealed respective significant
differences: for the RAs (1.1 0.3 vs. 2.7 1.5, P < 0.01); for the SAs
(1.1 0.3 vs. 2.7 1.0, P <0.001); for the AAs (1.0 0.25 vs. 2.8
1.0, P < 0.001). In all cases of AR, there was a decrease or annulation
of the diastolic phase; recuperation was marked by a progressive return
to the normal curve and by decrease of the previously raised P1. The
third group was made up of 6 patients (5 with RA stenosis, confirmed by
arteriography, and I with RA thrombosis). The five cases with stenosis
showed the existence of high velocity turbulence (>7 kHz) at the level
of the stenosis associated with the phenomena of aliasing; in the
thrombosis case, the curve was absent. Conclusions: DD appears to be
an important new diagnostic technique for the diagnosis of RT compli-
cations, especially in AR, RA stenosis and RA thrombosis.
Beneficial effect of calcium entry blocker drugs in experimental
cyclosporine A nephrotoxicity. L. Hernandez, D. Fonseca, A. Hens, A.
Martin-Malo, D. Castillo, J. Gomez, R. Perez, C. Vargas, R. Muñoz,
E. Moreno, P. A/f ama, Hospital Reina Sofia, Cordoba, Spain. The
acute renal dysfunction induced by cyclosporine A (CyA) depends on a
vasoconstrictor mechanism which might well partially be counteracted
by calcium antagonist agents. It has recently been suggested that
verapamil (VER) enhances the immunosuppressive effect of CyA.
Therefore we have studied the renal function profile in rats treated with
CyA and VER. Four groups of Wistar rats (220 to 250 g) with left
nephrectomy were considered: a) CyA 30 mg/kg/day (N = 11); b) CyA
and VER 10 mg/kg/day (N = 8); c) cremophore (CRE) as the vehicle of
CyA (N = 11); d) saline solution as control (CONT). Animals were
followed during 15 days. Some results obtained at the 10th day of the
study:
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Urea
mg/dl
Weight
g
Mortality
%
a) 950a,b 201a,b 45a
b) 580 239 0
c)440a 225 0
P < 0.05 vs. CONT; b P < 0.05 a vs. b
Rats treated with VER showed a significant less renal impairment when
compared with those receiving only CyA. CRE also induced toxicity as
evidenced by a rise in plasma urea concentration and body weight
decrease. These data seem to suggest that VER protects efficiently
against the renal toxicity of CyA even in the absence of ischemia.
Moreover, the CyA vehicle CRE itself induced renal dysfunctions
which are in addition to that observed during CyA administration.
Graft and patient survival of RD patients with non-A, non-B chronic
hepatitis after renpl transplantation. R. Matesanz, F. Liaño, L. Orte, F.
Ga. Martin, R. Marcén, .1. Ortuño, Hospital Ramón Y Cajal, Madrid,
Spain. We studied the evolution of 20 patients with chronic NANB
hepatitis diagnosed while on HD treatment (enzymatic elevation of
more than 6 months in the absence of cardiac failure hepatotoxic drugs
and seroconversion for virus A, B, CMV and EBV) after receiving a
first cadaver graft on azathioprine + prednisone followed for 2 to 6
years, and compared with other 140 transplanted patients on the same
conditions. None of them received CSP. No systematic pretranspiant
blood transfusions were given. There were not differences between
these two groups with respect of age, time on HD, HLA-A, B and DR
mismatching or follow-up after transplant. NANB patients, however,
were significantly more transfused pretransplant than controls (7.65 vs.
2.95 units/patient, P < 0.001). There were no significant differences in
patient survival between these two groups (89.7 vs. 82.5% at 4 years,
NS) but graft survival was much greater for NANB patients (89.7 vs.
58.7% at 4 years, P < 0.001). None of them developed cirrhosis or
hepatic failure and histologic signs of activity were scarce. Our data
point to a fairly good prognosis for HD patients with NANB hepatitis
after receiving a kidney transplant, and an excellent graft survival
perhaps conditioned by the combined immunosuppressive effect of
blood transfusions + hepatic disease. Chronic NANB hepatitis should
not be a reason to contraindicate or to postpone a renal transplantation.
Cytotoxic antibodies after kidney transplantation: immunoglobulm
class and specificity. R. Marcén, A. Ting, P.J. Miach, C.J. Taylor, P. J.
Morris, John Radcl(fl'e Hospital, Oxford, U.K. and Hospital Ramón y
Cajal, Madrid, Spain. The class and specificity of the cytotoxic
antibodies were investigated in sera collected during the first weeks
following transplantation from 55 first cadaver kidney donor recipients;
35 patients with functioning and 20 patients with failed grafts. No
patient had cytotoxic antibodies before transplant, but 71.5% (25/35) of
patients with functioning and 75% (15/20) of patients with failed grafts
developed them afterwards. The addition of dithiothreitol, which di-
gests 1gM antibodies, produced the disappearance of the cytotoxicity in
almost all positive sera from patients with a functioning graft. However,
in the patients with failed grafts, the class of immunoglobulin varied; 7
patients had only 1gM antibodies, and 7 presented both 1gM and IgG.
On the other hand, IgG antibodies appeared in 1 patient without
antibodies and in 5 patients with 1gM after graft nephrectomy. The
monoclonal antibodies blocked the cytotoxic activity in 5 out of 6
patients studied, with functioning grafts; in 4 patients with antibodies
anti-HLA DQ and in 1 patient with anti-HLA Class 1. In the patients
with failed grafts the blocking was seen in all 9 patients studied, in 8
patients by antibodies anti-HLA Class I, in 6 patients by antibodies
anti-HLA DQ and in 2 patients by antibodies anti-HLA Class II. These
results indicate that characterization of the antibodies could be useful in
the interpretation of a positive crossmatch when the patients are
regrafted since 1gM antibodies may not be damaging whereas IgG
antibodies are.
Reduction of morbidity with a triple drug protocol including
cydosporine (CY) in ren$ transplantation. L.M. Pallardo, A. Rochera,
M. Malo, J. Sanchez, J. Garcia, J. Cabezuelo, M. Girnenez, P.
Sanchez, Hospital General La Fe, Valencia, Spain. In order to analyze
the consequences of the introduction of cyclosporine (CY) in our
transplantation program we studied the evolution of 45 patients trans-
planted in 1985, immunosuppressed with prednisone (P) and azathio-
prine (AZA) (AZA group), and the 65 patients transplanted in 1986, and
treated with CY, 7 mg/kg, AZA 1.5 mg/kg for the first two months, and
prednisone, 30 mg/day. There were no significant differences pre-
transplant between these two groups. In order to make the results
comparable, the period of time analyzed was jn the group AZA until
May 1986, and in the group CY until May 1987. Results. Posttransplant
ATN was present in 53.3% and 38.4%, lasting 9.7 6.6 vs. 12 4.9
days (P. ns) in the group AZA and group CY, respectively. Acute
rejection episodes were present in 84.4% and 32.3% of patients (P <
0.001), being the mean hospital stay posttransplant of 24.3 13.6 days
vs. 14.9 7.5 days P < 0.001). Serum creatinine one month
posttransplant was 2.3 1.2 mg/dl in the AZA group, and 1.8 0.8
mg/dl in the CY group (P < 0.05). At the end of the period analyzed in
the AZA group, 12.1 4.0months, 34 grafts are functioning (75.5%), 8
having failed graft due to rejection and one because of arterial stenosis.
In the CY group, after a mean follow up of 11.9 3.6 months, 58 grafts
are functioning (89.2%) (P, ns, X2), having five of them failed because
of technical reasons (three arterial thrombosis and two urinary fistulae).
Two patients have died in each group because of infectious diseases.
The final serum creatinine was similar in both groups, 1.5 0.5 mg/dl
vs. 1.6 0.4 mg/dl (P, ns); the percentage of patients with arterial
hypertension was 67.6% vs. 70.9% in the groups AZA and CY,
respectively. However, more patients in group AZA had proteinuria
(0.5 g/day) 29.4% vs. 10.9% (P < 0.05). In the AZA group 21 patients
needed hospital admission on 43 occasions, that means a hospital stay
of 1.26 days/patientimonth, but it was only 0.60 days/patient/month in
the CY group. In conclusion, CY immunosuppression is more effective
than AZA to prevent rejection, and is followed by a reduced morbidity
rate.
Low doses of cyclosporine (CY), azathioprine (AZA) and prednisone in
renal transplantation: Immunosuppressive efficacy and reduced nephro-
toxicity. L.M. Pallrdo, J. Sanchez, J. Garcia, R.F. Moreno, A.
Rochera, J. Cabezuelo, Hospital General La Fe, Valencia, Spain. In
order to reduce CY nephrotoxicity, preserving the immunosuppressive
efficacy, eighty-three consecutive recipients of a kidney graft (one living
donor, nine second transplants) received CY, 7 mg/kg/day, adjusting
the doses in accordance with the plasma levels, AZA 1.5 mg/day for
two months, and prednisone 30 mg/day. Thirty-one patients (37.3%)
had ATN lasting 11.5 4.7days. In twenty-three patients (27.7%) acute
rejection episodes were diagnosed 14.1 15.6days posttransplant, all
corticosensitive except in one patient who responded to ATG. The
mean hospital stay after transplantation was 15.2 7.0 days. After a
mean follow up of 12.9 5.0 months, there has not been any
immunological graft failure; there were six technical failures (four
arterial thrombosis and two urinary fistulae), and two patients died with
a functioning graft at two and eight months posttransplant. Serum
creatinine in the whole group at one month was 1.8 0.8 mg/dl, and
current serum creatinine in the patients with ATN was 1.8 0.5 mg/dl,
and in those without ATN was 1.5 0.3 mg/dl (P < 0.05). Acute
nephrotoxicity was diagnosed in nine patients 105.0 70.4 days
posttransplant, in presence of CY plasma levels of 404 199.3 ng/ml,
and a serum creatinine of 2.1 0.3 mg/dl. By contrast we had to
increase CY doses higher than 7 mg/kg in four patients after severe
rejection and persistently low CY levels. In conclusion, this triple drug
therapy is very effective in preventing rejection, and the findings
suggest a synergism of low doses of CY and AZA in human renal
transplantation. Besides, this therapy has a reduced nephrotoxicity
comparing with conventional immunosuppressive protocols of CY.
Cadaver kidney transplant in hyperhnmunized patients (HP). A.
Andres, J.M. Morales, C. Prieto, L.M. Ruilope, N. Clarici, A. Arnaiz,
J.L. Vicario, J.M. Alcazar, J.L. Rodicio, Department of Nephrology
and Immunology, 10 Octubre Hospital, Madrid, Spain. HP (patients
presenting in a certain moment with circulating antibodies >50%)
represent a challenge for a renal program. During 1984 through 1986 a
total of 26 HP (11 males, 15 females, aged 36 10.5 years) received a
cadaver kidney graft in our unit. It represented 18% of the total number
of renal transplants (143). In HP, 61% presented with acute rejection
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that was delayed in 19.2% (after 6 months of evolution). A better graft
survival was observed in HP when HLA-DR matching showed 3 or
more identities than when only 1 or none identities was observed (90%
vs. 25%, P < 0.05). The finding of previous positive crossmatches (13
cases) did not assume a worse survival. The existence of positive
crossmatch between the donor and the older sera of the patient at the
moment of the transplant (4 cases) had no prognostic significance. The
evolution of the group of HP is compared with that of a group of 81 renal
transplant with very low risk (VLR) (not HP, age below 50 years and
first graft). The percentage of patients receiving cyclosporine A or
standard therapy was similar in both groups. During the follow-up no
significant difference was found for graft survival between HP (65%)
and VLR patients (80.2%) P = NS, nor for patient survival (92% vs.
92.5%, P = NS). Conclusions: 1) HP present a graft survival is not
significantly different from VLR patients; 2) HLA-DR compatibility
modulates the prognosis; 3) previous crossmatch has no prognostic
significance; 4) positive crossmatch with older sera of the patients at the
moment of the transplant does not influence the outcome of the graft.
High-risk patients transplanted with cadaver kidneys (CRT) and
treated with cyclosporine (CsA). M. Gonzalez-Molina, M. Cabello, M.A.
Frutos, G. Martin, B. Ramos, E. Lopez de Novales, Hospital Regional
de Mdlaga, Servicio de NefrologIa, Málaga, Spain. The results of a
series of 43 high-risk CRT patients treated with CsA are analyzed. The
patients had one or more of the following high-risk factors (HRF): age
between 50 and 61 years (N = 23); had never received blood transfusion(N = 7); hyperimmune (N = 11); re-transplanted (N = 2); previous loss
of transplant because of immunological factors. Control group com-
prised 108 CRT patients without HRF treated with CsA. The study
series comprised 26 males (60.4%) and 17 females (39.5%); the control
group contained 77 males (71.3%) and 31 females (60.4%). In every
case, the protocol of organ extraction and storage was the same; there
were no statistically significant differences between warm, rewarm and
cold ischemias times (P = NS), or between HLA incompatibilities, graft
survival, and incidence of rejection associated with their A, B, and DR
compatibilities.
Variable High-risk group Control G. P
Recipient age years 43.7 12.9 31.9 9.4 <0.001
Donor age years 35.1 15.6 28.0± 14.5 <0.05
ATN % 65.8 57.0 NS
Average stay days 14.6 7.9 13.4 6.8 NS
Creat. 18th month mg/dl 1.9 0.7 1.7 0.9 NS
Incidence of rejection % 28.2 36.4 NS
Respectively, mortalities were, 2.3% (1 patient), against 0%. Function-
ing graft survivals after 1 year were 84% in both groups. Conclusions:
The data confirm that in high-risk patients CsA gives comparable results
to the normal-risk control group; the observed differences may be due
to center effect.
Serum levels of class I HLA antigens in hemodialysis patients. R.
Matesanz, L. Orofino, ML. Villar, J. Herrero, P. Glez-Porque, J.
Ortuño, Hospital Ramón y Cajal, Madrid, Spain. Beta 2-microglobulin,
the light chain of class I HLA antigens has been recently identified as
the main component of dialysis-related amyloid deposits. There are,
however, several aspects of this syndrome which are still not well
understood. We investigated the behavior of the complete molecule of
class I HLA antigens (alpha and beta chains) released from cell
surfaces. Serum levels of free HLA were measured by ELISA (J
Immunol Meth 65:373, 1983) (normal 2 to 5 tgIml). Seventy-four
patients on HD for 0, 5 to 10 years, always treated with cuprophan
dialyzers were studied. Only one of them has carpal tunnel syndrome
after 10 years on HD. Serum levels of HLA were over normal range in
89% of patients (: 18.4, upper range 160 g/ml). There was not a
significant correlation between HLA levels and time on HD, age,
residual diuresis, urea and creatinine levels, nor differences with
respect to sex or primary nephropathy. We find, however, a slight but
significant correlation between HLA and beta 2-MG (r: 0.6095, P <
0.01) but with marked individual variations. Serum levels fell during the
first 20 minutes of dialysis sessions (Cuprofan: 7.6%, AN-69 12%,
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EVAL 11.2%) with a further rise nearly up to the previous values at 4
hours. However, when corrected for total blood proteins, HLA profiles
were similar with the 3 membranes: initial decrease (25 to 35%) and
further partial recovery (15 to 20%). As with beta 2-MG, HLA levels are
increased in HD patients. During dialysis sessions there is an initial
decrease, whatever the membrane employed, with further recovery.
Eventual pathogenic implications of these facts remain uncertain.
Studies on the mechanisms of action of desmopressin (DDAVP) on
primary hemostasis in uremic patients. A. Cases, G. Escolar, J.
Monteagudo, A. Ordinas, J. Lopez-Pedret, R. Castillo, L. Revert,
Nephrology and Hemotherapy Services, Hospital Clinic, Barcelona,
Spain. Desmopressin (DDAVP) is known to improve uremic
thrombopathy (UT), although its mechanisms of action are not clearly
established. The aim of this study was to investigate the effects of
DDAVP on primary hemostasis in UT. Eleven uremic patients with UT
defined by a bleeding tendency, a prolonged bleeding time and an
abnormal platelet aggregation were studied. DDAVP (0.4 pg/kg) was
infused i.v. over 20 minutes. Prior to, and 1 and 6 hours after the
infusion bleeding time, platelet retention and platelet-subendothelium
interaction were measured. Moreover plasma levels of FVIII-related
activities and catecholamines were measured. To elucidate whether the
increase of von Willebrand factor (vWF) was responsible for the
improvement of uremic thrombopathy, platelet-subendothelium inter-
action was studied with uremic plasma before and after the addition of
1 U/mI of vWF or I U/mi of vWF + 1 U/mi of FVIII. One hour after
infusion there was a significant shortening of bleeding time (P < 0.05)
and an improvement of platelet retention (P < 0.05), although this effect
was lost 6 hours later. Moreover after 1 hour there was an increase in
plasma norepinephnne, FVIII and vWF (P < 0.05). There was also an
improvement in the parameters that quantitate platelet-subendothelium
interaction (P < 0.05). The addition in vitro of I U/mI of vWF or 1 U/mI
of vWF + I U/mI of FVIII did not improve platelet-subendothelium
interaction. These results prove that the improvement in UT is due to a
factor or factors present in plasma after DDAVP infusion. This effect
does not seem to be due to a quantitative increase in FVIII-related
activities. The increase in plasma norepinephrine, through its interac-
tion with platelet a-adrenergic receptors, might play a role in DDAVP-
induced improvement in uremic thrombopathy.
Interaction of von Willebrand factor with platelet membrane GPIb in
uremic patients. A. Cases, J. Monteagudo, G. Escolar, J. Lopez-
Pedret, L. Revert, R. Castillo, Nephrology and Hemotherapy Services,
Hospital Clinic, Barcelona, Spain. The interaction of von Willebrand
factor (vWF) with glycoprotein lb (GPIb) of platelet membrane plays a
principal role in the adhesion of platelets to vascular subendothelium.
An impairment in platelet adhesivity has been found in uremic
thrombopathy. These data suggest that an impairment in the GPIb may
be responsible for the decreased platelet adhesivity in uremic patients.
Structural and functional studies of GPIb were carried in 8 uremic
patients and 8 controls of similar age and sex. Uremic patients showed
a prolonged bleeding time, an impairment of ristocetin-induced platelet
aggregation and a decrease in platelet-subendothelium interaction.
Platelet membrane glycoproteins were studied by crossed radioim-
munoelectrophoresis. Binding of vWF to GPIb was performed by
incubating increasing concentrations of '251-labeled highly-purified
vWF with washed uremic platelets, and the interaction was induced
with 1.5 mg/mI ristocetin. The electrophoretic pattern of platelet
membrane glycoproteins was normal in uremic patients. Moreover,
saturation and time-course experiments were not altered in these
patients. These results demonstrate that the altered platelet adhesion to
vascular subendothelium cannot be ascribed to structural or functional
disturbances of platelet membrane GPIb in uremia.
Synthesis of lymphokines in patients on hemodialysis. M. Gonzalez,
J.G. Cotorruelo, A.L.M. de Francisco, F. Canga, E. de Bonis, S. Sanz
de Castro, M. Arias. The uremic patient develops an immunodeficiency
status that has been demonstrated in some in vitro studies. Interleukin-2
(IL-2) being one of the principal immunoregulatory proteins, we have
studied the synthesis of this lymphokine in patients undergoing hemo-
dialysis. Thirteen patients on hemodialysis and 6 blood donors as
controls were used in this study. T lymphocytes were isolated by
density gradient followed by incubation with sheep red blood cells
(rosette formation). The cells were incubated with phytohaemagglutinin
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(1%) in atmosphere with 5% of CO2 at 37°C. The supernatants were
collected at 24, 48 and 72 hours. In order to test IL-2 activity an IL-2
dependent cell line, CflL-2, was cultured supplemented with the
supernatants at different dilutions (1/32, 1/16, 1/8, 1/4). Recombinant
IL-2 was used as control (10 and 100 U/mI of Recombinant Human
Interleukin, Hoffmann-Laroche Inc.) IL-2 synthesis in the uremic
patient was lower than in controls (P < 0.02) but with peak production
at the same time (24 hours).
24 hours 48 hours 72 hours
Controls 16.868 10.515 7.726
Uremic 8.938 8.386 7.611
x of CflL-2 proliferation with supernatant (dilution 1/4). In uremia the
synthesis of IL-2 is diminished, and as this lymphokine is fundamental
in the immunoregulation, its deficit could be one of the mechanisms of
the immunodeficiency in uremia.
Comparative randomized study of lnsulln administration through two
different routes in CAPI) diabetic patients. J.J. Diez, F. de Alvaro, J.
Muñoz, C. Miguelez, V. P-Diaz, N.S. Jabari, K.L.-Revuelta, S. Cigar-
ran, R. Se/gas, Hospital La Paz, Madrid, Spain. Up-to-date route
election for insulin administration in diabetic patients on CAPD has not
been definitely defined. Our aim has been to know whether subcutane-
ous (s.c.) or intraperitoneal (i.p.) route makes any difference in meta-
bolic control or peritonitis incidence in these patients. M.M.: two
groups from different hospitals with a similar peritonitis incidence (1
event/24.3 patient-months) were studied. CAPD system was Ultraviolet
chamber for bag change. Groups were similar for epidemiological data.
13 were treated with s.c. insulin and 6 with i.p, The follow-up period
was 9 months. Biochemical parameters (urea, creatinine, potassium,
hemoglobin, transferrin, cholesterol and triglycerides) did not differ in
baseline or following checks. Peritoneal diffusion parameters for urea
and creatinine were similar. Peritoneal glucose load was slightly higher
in the i.p. group. Results: Insulin requirements were 28 14 U/day in
s.c. and 90 62 U/day in i.p. group (P < 0.05). Metabolic controls:
home glycemia profiles before the three meals once a week and
summarized every two months were similar for both groups; mean
hospital fasting, glycemia was also similar (109 to ISO mg/dl); the
number of hypoglycemias registered was two per month in all patients.
Hb Al C levels were between 6 and 9% with no differences for both
groups. All of these features allow us to recognize a similar metabolic
control. However, peritonitis incidence was 3.2 times higher in the i.p.
group with a similar distribution of etiological germs. We conclude that
intraperitoneal insulin route represents a higher risk for suffering
peritonitis with no metabolic real improvement.
Peritoneal functional parameters after five years on CAPD. S. Cigar-
ran, R. Selgas, J. Munoz, P. Ramos, K. L-Revuelta, F. Escuin, J.L.
Miguel, Hospital La Paz, Madrid, Spain. Functional stability of the
peritoneum is essential for CAPD patients (pts) at long-term. Scanty
information about this subject has been published. Sixteen ESRD pts on
CAPD during 5 years were studied. Mean age was 47 iSyears. There
were S males, no one diabetic. Seven of them were taking betablockers
(BE) during the period and 6 showed high blood pressure (HT).
Residual renal function was 2.1 2.6 mI/mm. We evaluated their
peritoneal ultraffitration rate (UF) and diffusion parameters at least
once a year. Mathematical modeling techniques were applied to obtain
the peritoneal mass transfer coefficient (MTC, mI/mm) for urea and
crearinine. To distinguish the effect of peritonitis (P), BB and HT, pts
were properiy grouped. In the overall group, initial and final urea-MTCs
were respectively 20.6 5.4and 18.8 4.2 (P = NS); creatinine-MTCs
were 9.6 4.4 and 9.2 2.4 (NS); UFs were 1.4 0.4 and 1.4 0.5
(NS). Effects of P: early P (<24 months) did not show to influence any
of the peritoneal parameters; however, late P induced a decrease in
urea-MTC (22.3 6 to 15.8 3.9, P <0.05), creatinine-MTC (9.4 3.1
to 7.4 2.1,P < 0.05) and the corresponding increase in UF (1.25 0.4
to 1.4 0.3, P C 0.05). Age and sex did not influence the peritoneal
parameter follow-up. Neither BE nor HT induced significant changes
on UF and MTCs. In conclusion, after 5 years on CAPD, functional
stability of the peritoneum seems to be warranted except in the patients
who suffer late episodes of peritonitis (in CAPD for more than 2 years).
Probably, "older" peritonei are more susceptible to injuries than
younger ones.
Acetate "slow metabolizers": A real phenomenon? J. Torrente, M.C.
Ruiz-Gonzalez, J.C. Diez-Baylon, F. Coronel, A. Barrientos, Service
Nephrology, Hospital Universiiario San Car/os, Madrid, Spain. Some
hemodialysis (HD) patients (pts) have shown progressive increase in
serum acetate (Ac) along with severe decline in CO3Er (so-called
"slow metabolizers"). We studied the accumulation pattern of Ac in 6
selected patients (3 with Ac > 9 mmol/liter, group I; 3 with Ac C 4
mmol/liter, group II). Na-Ac i.v. infusion at maximal metabolic rate
reported (3.6 mmol/kg/hr) was performed. In 2 pts, the first one with the
higher Ac on HD and the other with the lower, we calculated the mass
balance of Ac and C03H along HD. We found a strong negative
correlation between body surface and Ac (r =
—0.58, P C 0.001) and a
positive one of body surface vs. CO3W (r = 0.48, P C 0.01); 11% of pts
were hyperacetatemic (Ac > 6 mmol/liter), those with lower body
surface. There was no difference in Ac after maximal Na Ac infusion in
group I vs. 11(2.3 0.7vs. 2.7 0.6). The mass balance ofAc indicated
that in spite of clear difference in maximal Ac (12.9 vs. 2.9 mmol/liter)
between patients, Ac was metabolized at similar rate (4.7 vs. 4.2
mmol/kg/hr) in both the hyper- and the lower cases. The mass balance
of C03H showed higher losses per kg of body weight in pts with lower
body weight. Our results suggest: 1) The Ac accumulation is inversely
related with body mass. 2) The Ac metabolism is similar in spite of Ac
accumulation. 3) CO3H decline is related to excessive CO3H losses in
small patients. 4) The typical pattern of so-called "slow metabolizers"
is a body mass-related phenomenon.
Visual and auditory toxicity in desferrioxamine-treated hemodialyzed
patients: A prospective study. A. Cases, J. Kelly, F. Sabater, A. Torras,
J. Campistol, M.C. Grino, J. Lopez-Pedret, L. Revert, Nephrology,
Ophthalmology and ENT Services, Hospital Clink, Barcelona, Spain.
The aim of this protocol was to study the incidence and characteristics
of desferrioxamine (DFO)-induced audiovisual toxicity. We studied
over a year period 37 hemodialyzed patients that received DFO for the
first time. Before starting the treatment and periodically visual (visual
acuity, Farnsworth test, funduscopic examination) and auditory
(audiogram) function were tested. A) Visual toxicity: 7 patients showed
an acquired dischromatopsy in the Farnsworth test (6/7 of tritan type),
3/7 patients complained of clinical toxicity characterized by a decrease
in visual acuity, dischromatopsy and night blindness (1 patient). One
patient showed pigmentary perimacular deposits. Clinical toxicity im-
proved upon drug withdrawal, but tritanopy only reversed in 2 patients
several months later. B) Ototoxicity: 5 patients showed neurosensorial
hearing loss in the audiogram. Two of 5 patients showed acute and
clinical toxicity, while in the rest it was subclinical. All patients
improved upon drug withdrawal. Audiovisual toxicity is a frequent
complication of hemodialyzed patients treated with DFO. This toxicity
may be acute and clinical or subclinical. We recommend serial audio-
visual monitoring of audiovisual function in uremics receiving DFO.
Visual acuity and Farnsworth tests, as well as audiogram are easy and
valuable tools for eariy detection of visual and auditory DFO-induced
toxicity.
Sepsis in bemodialyzed patients: A prospective study, J.A. Martinez,
A. Cases, X.M. Lens, J.M. Gatell, J. Montoliu, J. Lopez-Pedret, L.
Revert, Infectious Diseases and Nephrology Services, Hospital Clinic,
Barcelona, Spain. To study the incidence and characteristics of sepsis
in hemodialyzed patients a prospective study was performed during 38
months (June 1983-September 1986) in three dialysis units. Initially 326
patients were included, during the study 212 new patients started
hemodialysis (HD), 57 patients died and 102 were lost. A total of 13376
months of HD were completed. Seventy-five episodes of sepsis in 64
patients were recorded, with an incidence of 5.6 episodes/bOO treat-
ment months. The most frequent source of infection was the vascular
access (64%) and among them the catheters used as transitory vascular
access (37%), while definitive vascular access (27%), urinary tract
infections (10%) and respiratory infections (6%) were other frequent
sources. During the first two months of HD 27 episodes of sepsis in 24
patients were recorded (11% of all new patients), in this group the most
frequent source were the catheters used as temporary vascular access
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(73%), while in the rest of patients the most frequent source was the
definitive vascular access. The most frequent organisms were gram
positive bacteria (72%), specially Staphylococci Aureus and Epidermi-
dis (60%), gram negative bacilli (25%) and candida (3%). Staphylococ-
cus were significantly related to vascular access (P < 0.01), while gram
negative bacilli were related to a source other than blood access device
(P < 0.05). Major complications recorded were: 2 endocarditis on the
aortic valve, 1 hemorrhagic shock because of a micotic aneurysm in the
AV fistula and 1 thrombophlebitis with persistent bacteremia. 11/75
cases died (14.6%), it constituted 19% of the total of deaths. Hepatic
cirrhosis and a source other than vascular access were significantly
associated with a higher mortality. Sepsis remains to be a major cause
of morbidity and mortality in hemodialyzed patients. The most frequent
source was the vascular access and specially catheters used as transi-
tory vascular access. The most frequent bacteria were Staphylococci.
The presence of hepatic cirrhosis and a source other than vascular
access were factors of poor prognosis.
Clinical, biochemical and anthropometric changes induced by oral
dietetic supplements in patients undergoing chronic hemodialysis. E.
Pelaez, L. Orofino, R. Marcén, R. Matesanz, C. Quereda, J.A.
Herrero, I. Zamarrón, J. Ortuño, Servicio de JVefrologia, Hospital
Ramon y Cajal, Madrid, Spain. Progressive weight loss with or without
modification in nutritional parameters, is frequent among chronic
hemodialyzed patients. We study the effect of oral dietetic supplements
administration in 10 patients (6 male and 4 female), with a mean age of
51.9 years (21-64 years), being in dialysis for 81.5 months (5-116
months). Those patients presented with a weight loss of 1.85 kg, P <
0.01, with intense anorexia, without infection nor other intercurrent
illness, during the previous 3 months. Oral supplements consisted in
1000 mi/day of a maltose hydrolyzed derivative; the mean follow-up
was 5.5 months and no changes were introduced in dialytic procedure.
We measured the dry weight (DW), midarm muscular circumference
(MAMC), tricipital skinfold thickness (TST), hemoglobin (Hb), albumin
(A), transferrin (T), prealbumin (PA), retinal binding protein (RBP),
protein catabolic rate (PCR), vitamin A (VA), vitamin E (VE), lympho-
cytes total count (LYMPH), every month and systolic blood pressure
(SBP), at the beginning of each dialysis. The results were as follows:
Stage DW MAMC TST
Initial
Final
48.7 5.9
50.6 53 23.3 1.823.5 1.4 7.1 2.98.3 2.5
Stage Hb A PCR
Initial
Final
9.0 2.2
9.9 2.9
3.08 0.4
3.2 0.1
1.12 0.2
1.41 0.la
a p < 0.01
Stage T PA RBP
Initial
Final
242 110
256 83
29.8 8.5
28.6 9.9
21.5 7.0
18.6 5.6
Stage VA VE LYMPH
Initial
Final
98.0 43
112.6 38
1228 225
1146 379
1689 770
1752 744
Treatment was stopped when there was a recovery of a 100% of weight
lost in the previous 3 months, Tolerance was good; interdialysis weight
increase and SBP did not change during the study. Conclusions: I.)
There was not correlation between dry weight loss and usual nutritional
parameters. 2.) The progressive weight loss was controlled in all cases
with recovery of 100% of weight loss. 3.) The significant increment of
protein catabolic rate confirms effectivity of treatment.
Antiproteinuric effect of indometbacin. J. Ballarin, F. Calero, A.
Oliver, P. Barceló, R. Castellet, E. Servitje, D. Sans, G. Del RIo,
Fundacion Puigvert, Barcelona, Spain. Although the antiproteinuric
effect of indomethacin is well known (I) its action mechanism is not yet
completely solved. We have performed a random double-blind test
(indomethacin versus placebo) with paired data in 9 patients following
a therapeutic pattern: 1 (50 mg/8 hr) P during 15 days, I/P +
hydrochlorothiazide (HZ) 15 days, P/I 15 days, P/I ÷ H2 15 days. At the
end of each course the following parameters were determined: plas-
matic creatinine, 24 hrs. proteinuria, proteinuria selectivity albumin,
IgG, haptoglobin, macroglobulin) and plasmatic renin activity (RIA).
The statistic comparison was performed with Student's test for paired
data.
Basal I I+HZ P P+HZ
Creatinine m
DS
1.2
0.7
l.2a
0.6
l.2a
0.6
l.3a
0.1
l.4
1.1
Proteinuria m
DS
4.6k'
18b
3.oa
2.1
20b
1.0
4.0
2.5
3.8
2.4
ARP m 39 0.5C 2.3a 2.3 7.7
ng/ml/hr DS 2.5C 0.4 1.9 1.6 49
a NS, b p < 0.01, P < 0.005
In two patients with previous renal failure an increase of creatinine was
observed. Conclusions: Indomethacin has only an antiproteinuric effect
in patients with hydrosalin depletion. We have not found a correlation
between the ARP inhibition, the creatinine increase and the diminishing
of the proteinuria. This action is probably related to the inhibition of the
synthesis of intrarenal prostaglandin.
Anti-glomerular basement membrane antibody (Anti-GBM) glomeru-
lonephritis (GN): Should patients with renal insufficiency be treated? M.
Praga, F. Gutierrez Rodero, A. Andres, A. Oliet, C. Lumbreras, J.M.
Morales, V. Gutierrez-Millet, 1. Bello. The use of aggressive treatment
(plasma exchange, steroids, cyclophosphamide) in anti-GBM GN with
severe renal function derangement remains a controversial issue. Some
groups, based on their previous poor results, do not treat those cases
presenting with oligoanuria or renal insufficiency requiring dialysis. We
describe our experience with 6 cases of anti-GBM GN and severe renal
function derangement. Their age ranged between 27 and 73 years (X
48.6 16.7 years). Lineal deposition of IgG along the GBM together
with circulating anti-GBM antibody were detected in every case. The
serum creatinine (Sc-) oscillated between 5 and 13 mg/dl (X 8.9 3.2
mg/dl). Two patients presented with oligoanuria (daily diuresis <25 ml)
and institution of hemodialysis was necessary in 4 patients. Renal
biopsies showed crescents in 60 to 90% of glomeruli (X 79 13.4%). All
the patients were treated with metilprednisolone pulses (1 gram i.v. on
three consecutive days) followed by oral steroids and cyclophospha-
mide. In addition, plasma exchange was performed in five cases (6 to 24
sessions, X 14.8 7.4). One patient did not recover renal function and
he was included in chronic hemodialysis treatment; on the other hand,
five patients showed an evident improvement of renal function: one
case died on the 60th day of evolution due to massive pulmonary
hemorrhage, but his Scr had decreased from 5 to 3.4 mg/dl. In the
remaining four patients the initial SCr had dropped from 9.4 3.2 mg/dl
to 5.6 3.4 mg/dl on the 30th day and to 3.5 1.3 mg/dl on the 60th day
after the initiation of treatment, and remained stable on the follow-up.
The most distinctive fact in the patient that not recovered renal function
was the circumferential character of the crescents, that collapsed the
glomerular tuft; the remaining patients have, on the contrary, segmental
crescents. Therefore, most (5 out of 6) of our patients showed a clear
improvement of renal function after the initiation of treatment; this
improvement allowed the discontinuation of dialysis in 3 out of 4 cases
that needed it at presentation. We concluded that the need of dialysis or
the presence of oligoanuria are not, in our experience, valid criteria to
discard the employment of potentially useful therapy in anti-GBM GN
patients.
Height attainment in children with steroid-responsive nephrotic syn-
drome (SRNS). A. Vallo, M. Ubetagoyena, F. Ariza, M. Sanchez, R.
Oliveros, M.J. Quintela, J. Rodriguez Soriano, Division of Nephrology,
Hospital Infantil de Cruces, Bilbao, Spain. Stunting of growth is a
complication of steroid therapy. This effect is already evident after a
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course of 3 months of steroid therapy given to treat one single episode
of nephrotic syndrome: in 60 nephrotic children, the standard deviation
score (SDS) of growth velocity became negative during steroid admin-
istration (3.0 2.6) and the height SDS decreased from 0.26 1.2 to
0.007 1,2 (P < 0.001). We studied a group of children with SRNS
submitted to repeated courses of steroid therapy to determine the
possible correlation between height attained and total dose of predni-
sone administered. Seventy-seven patients (56 male, 21 female) diag-
nosed as having SRNS were studied. Mean age at diagnosis was 5.4
2.5 years, and the time of follow-up was 4.2 3.2 years. All patients
had been treated with standard doses of prednisone following the
recommendations of the ISKDC. Mean number of relapses was 5 4
(1.9 1.1 relapses/year). Mean total prednisone dose was 13400
11100 mglm2. Results. Height SDS at the end of follow-up was not
significantly different from height SDS at diagnosis. However, signifi-
cant correlations existed between height SDS at the end of follow-up
and both number of relapses (r =
—0.42, P < 0.01) and total amount of
prednisone received (r = —0.39, P < 0.01). To determine whether
catch-up growth occurs once treatment is stopped, the patients were
divided into two groups. For 39 children who had been off treatment for
at least one year no correlation was present between height SDS and
total amount of prednisone received, but this correlation was significant
for 38 children who had been submitted to at least one course of therapy
during the previous year (r = —0.53, P < 0.001). Comments. Steroids
suppress growth in children with SRNS at the time of its administration
and this effect is dependent upon the total dose received. However,
repeated courses of steroid therapy do not affect the final height owing
to the catch-up growth taking place on the periods off therapy. The
prognosis of ultimate height may be less favorable when prolonged
maintenance therapy with large doses of steroids is required.
HLA-A, B, DR and Bf allotypes in untreated idiopathic membranous
nephropathy in adults. A. Gonzalo, A. Arnaiz, J.L. Vicario, N. Clerici,
J. Ortuño, Nefrologla e Immunologla. Hospital Ramón y Cajal, Hos-
pital J0 de Octubre, Madrid, Spain. Seventeen patients with untreated
idiopathic membranous nephropathy (LMN) were studied. At the time
of diagnosis all presented nephrotic syndrome (NS) and normal renal
function. The mean follow-up was 6 years (range S to 8 years). At the
end of follow-up 6 patients were in complete remission and 11 had
persistent NS (three of them with chronic renal failure). Seventeen
patients were typed for HLA ABC and DR antigens (micro-
lynphotoxicity test) and 15 for Bf allotypes (electro-immuno-fixation).
The controls were 450 for ABC, 63 for DR and 330 for Bf. The DR3
antigen frequency in patients (64.7%) was significantly increased (PcxlO
< 0.005) with respect to the controls (17.4%). The DR3 frequency in
patients who remitted (100%) was higher than those with NS (45%), but
the relation was not significant. The B8 and B18 antigens frequency
(23.5%) in patients was not significantly different from the controls
(11.3% and 14.6%, respectively). B8-BfS-DR3 and B18-BfF1-DR3
haplotypes were associated neither with remission nor with NS. The
BfFI gene frequency was 0.184 (33.3%) in patients and 0.052 (10%) in
controls (Pcx4 > 0.05). So, IMN is a strongly HLA-DR3 linked disease.
The previously reported association with BfFI allele and with HLA-
B18 cannot be deduced from this study.
Histogenesis of glomerular crescents (GC) in idiopathic extracapilar
proliferative glomerulonephritis (EPGN): Clinical implications. J. DIez,
F. Pardo-Mindán, A. SdnchezCasajas, University Clinic, Pamplona,
Insalud Hospital, Logrono, Spain. It is not clear as to what cells are
responsible for the formation of GC in EPGN. We therefore studied 20
biopsies of idiopathic EPGN through the use of light and electronic
microscopy and the use of immunohistochemical techniques. We di-
vided the EPGN in two groups: 1) eight EPGN with crescents formed
predominantly by the visceral epithelium and, 2) twelve EPGN with
crescents formed predominantly by the parietal epithelium. In the first
group, the GC were immediately infiltrated by macrophages, laminine,
fibronectine and type IV collagen until total hyalinization of the
glomerulus was produced. These EPGN developed rapidly (7.13 3.5
weeks), presenting frequently with intense asthesia, edema, severe to
massive proteinuria, frank hematuria and severe renal insufficiency. Its
response to treatment (corticosteroids + immunosuppressives plas-
mapheresis) was poor. After 16 months of follow-up (3 months to 3 year
interval) in 7 surviving patients, I presented normal renal function and
6 were found to be included in hemodialysis (HD) program. In the
second group of EPGN, the GC was formed by the parietal epithelium
and a combination of inflammatory cells and periglomerular fibroblasts
that formed a type III collagen to total glomerular fibrosis. In these
patients the disease developed more slowly (40 11 weeks) and the
nephropathy manifestations were less aggressive than the previous
group. Its response to treatment seems to be more favorable as 9
survived after 24 months of follow-up (3 months to 7 year interval), 5
presented chronic renal insufficiency and 4 were found included in HD.
We conclude that electron microscopy and the immunohistochemical
methods aided in distinguishing these two types of EPGN which have
different histogenesis, clinical presentation and prognosis.
Treatment of hypertension with serotoninergic S-2 receptor blockers.
L. Carreras, A. Martinez Amenós, H. Rama, X. Sarrias, J. Alsina,
Service of Nephrology, Hospital de Bellvitge "Princeps d'Espanya",
Barcelona, Spain. Thirty-three volunteers with mild essential hyperten-
sion after 4 weeks with placebo were included in a cross-over double
blind treatment protocol with the serotoninergic S-2 receptor blocker,
Ketanserin (K), 40 mgll2 hrs vs. Metoprolol (M) 100 mg/12 hrs.
A Period B Period C Period D
0 3 3 6 9 Il2months
'TAD 90: Ketanserin in monotherapy I
&tanserinJ : aceboTAD> 901 Ketanserin + metoprolol4 TAD 90: Ketanserin
monotherapy
tetoprolol Ketanseri] Placebo
monotherapy
I TAD > 90: Ketanserin +
I Metoprolol
M was effective in 69.7% of 17 patients, K was effective in 56.25% and
reduced resting (R) systolic pressure (SP) by 11.57 and DP by 9.54%
and standing (5) SP by 11.49 and DP by 8,42%, respectively. After one
year K was effective in 33% of all patients for R and S. The association
of both drugs at the same dose in patients refractory to single drug
treatment improved arterial pressure in 41.17%, K obtained a mild
reduction in HP, particularly in the first 6 months with satisfactory
tolerance-drowsiness in 22.5% of patients versus bradycardia, requiring
suspension of the drug in 10.71% with M. There is mild potential of the
association of M+K, without age-related effects and without biological
or hematological alterations.
Approach to the pressor mechanisms of alcohol: Effects of ethanol on
membrane Na+ transport systems. A. Coca, R.P. Garay, MT. Aguilera,
A. de la Sierra, J. Montoliu, A. Urbano-Márquez, Servicio de Medicina
Interna General, Hospital Clinico y Provincial, Facultad de Medicina,
Universidad de Barcelona, Spain, and INSERM U7/CNRS LA 318,
Hópital Necker, Paris, France. Several epidemiological and clinical
studies have established a clear association between alcohol consump-
tion and hypertension. A chronic alcohol intake of 30 g/day or more
rises blood pressure in essential hypertensives, which decreases signif-
icantly on cessation of drinking. However, this effect has not been
clearly demonstrated in normotensives, suggesting that the effect of
ethanol is not uniform in both hypertensives and normotensives. The
mechanism of this effect is unknown. Recent reports have described
intracellular modifications of Na, K, Ca and Mg + in alcoholics,
suggesting to us that ethanol may rise blood pressure through the
interaction with Na transport systems. This interaction could presum-
ably be different on normal cells and on cells with genetically-altered
Na transport systems, supporting the heterogeneity of the pressor
effect of alcohol. To test this hypothesis we have studied the in vitro
effects of different amounts of ethanol (32 up to 400 mM) on the Na
fluxes catalyzed by Na-K ATPase, Na-K cotransport, Na-Li
countertransport and passive Na+ leak in human erythrocytes with
physiological Na content. A particular attention was focused to
determine the effect of ethanol on the kinetic properties of Na-K
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pump and Na+K+ cotransport: apparent affinities for internal Na
(K50%) and maximal rates of Na effiux (Vmax). Ethanol at concentra-
tions higher than 32 m stimulated ouabain-sensitive Na effiux. This
effect resulted from an increased Vax without any significant effect on
the apparent affinity of the Na-K pump for internal Nat At the same
concentrations, ethanol inhibited bumetanide-sensitive Na effiux by
decreasing Vmax, with no effect on K50%. On the contrary, both
Na-Li countertransport fluxes and Na leak were stimulated. All
these interactions were reversible. We conclude that ethanol modifies in
vitro erythrocyte Na+ transport function even at concentrations similar
to those present in blood of moderate drinkers. With the exception of
Na-K pump, alcohol-induced alterations are similar to the observed
in erythrocytes of essential hypertensives. Therefore, chronic alcohol
consumption could potentiate those genetic abnormalities of Na
transport and contribute to the pathogenesis of essential hypertension.
Transmembranous Na+ transport abnormalities in essential hyperten-
sion. Is it useful the study in erythrocyte with a physiological Na
content? A. de Ia Sierra, A. Coca, M.T. Aguilera, J. Montoliu, A.
Urbano-Márquez, Servicio de Medicine Interna General, Hospital
ClInico y Provincial, Facultad de Medicina, Universidad de Barcelona,
Barcelona, Spain. Several epidemiological, clinical and experimental
studies have evidenced a clear relationship between excess Na intake
and essential hypertension. The considerable progress in the under-
standing of Na metabolism at molecular level has allowed the detec-
tion of genetic abnormalities of Na transport systems with a variable
frequency depending on racial and ethnic factors. The aim of this study
was to detect these abnormalities and to establish their relative fre-
quency in a sample population of essential hypertensives from the area
of Barcelona, Spain. Using the method described by Garay et al
(Biochem Pharmacol 1984;33:2013—2020) we have studied the Na
effiux dependent on Na-K ATPase, Na-K cotransport, Na-Li
countertransport and passive Na leak in fresh erythrocytes from 72
essential hypertensives and 30 normotensive controls. Na-K pump
activity was considered as the ouabain-sensitive Na effiux. The
ouabain-resistant, bumetanide-sensitive Na effiux was assumed as the
Na-K cotransport activity. The ouabain, bumetanide-resistant, Li-
stimulated Na efflux was equated to Na-Li countertransport and,
finally, ouabain and bumetanide-resistant Na effiux in a sucrose-Mg +
medium was considered as passive Na leak. When both samples of
normotensives and hypertensives were compared, a significant differ-
ence was found in only the Na effiux dependent on the Na-Li
countertransport, which was higher in hypertensive subjects (P =
0.0105). Nevertheless, when the 95% confidence limits of the different
Na fluxes in the normotensive group were used as a cut-off point of
normality, 24 patients (33.3%) showed some alteration of their Na
transport systems: 3 (4.2%) exhibited a decreased Na efflux dependent
on ATPase, 6 (8.3%) a decreased Na effiux dependent on cotransport,
8 (11.1%) an increased Na effiux dependent on the countertransport,
and 7 (9.7%) an increase in passive Na leak. The remaining 43 (59.7)
hypertensives did not present any evident alteration. We conclude that
abnormalities of Na transport detected in erythrocytes with physio-
logical internal Na content are unable to discriminate the whole
population of hypertensives from the normotensives, as they are found
in only one-third of patients. The fact that most of essential hypertensives
did not show any abnormality of their Na1 transport systems under such
experimental conditions does not allow to assert their lack. Further
investigations including kinetic properties of active Na transport systems
and their response after erythrocyte Na load are required.
Transmembranous Na+ transport abnormalities in essential hyperten-
sion. A kinetic study of active transport systems. A. de Ia Sierra, A.
Coca, M.T. Aguilera, J. Montoliu, A. Urbano-Marquez, Servicio de
Medicina Interna General, Hospital Cilnico y Provincial, Facultad de
Medicina, (Jniversidaci de Barcelona, Barcelona, Spain. In a previous
report we described abnormalities of Na efflux dependent on Na-K
ATPase, Na+K+ cotransport, Na-Li countertransport and passive
Na leak, exhibited by only one-third of 72 essential hypertensive
patients, when transport systems were studied in erythrocytes with
physiological internal Na content. These results confirm that measure-
ment of Na fluxes under such experimental conditions are not useful,
neither to discriminate samples of essential hypertensives from
normotensives nor to individualize essential hypertensive patients on
the basis of their abnormalities in Na cellular metabolism. Modifying
the intraerythrocytic Na content through the anion carrier, we have
studied in the same 72 essential hypertensives and 30 normotensives,
the kinetic properties of Na-K ATPase, Na-K cotransport and
Na-Li countertransport. Internal Na content required for half-
maximal stimulation (K50%), that measures the affinity of the carrier for
its substrate, and maximal translocation rates (Vmax) were the kinetic
parameters determined. We only observed a significant increase in Vax
(P < 0.0001) and K50% (P = 0.0079) of Na-Li countertransport in
essential hypertensives when they were compared with normotensives.
Nevertheless, using 95% confidence limits in the normotensive group as
a cut-off point of normality, 67(93.06%) essential hypertensives showed
some abnormalities in their kinetic parameters: 12 (16.67%) presented a
decreased apparent affinity of ATPase for internal Na, defined by
increased values of K50% ("Pump -" hypertensives); 20 (27.7%) a
decreased apparent affinity of cotransport for internal Na ("Co
hypertensives); 27 (37.5%) an increased Vmax of countertransport
("Counter +" hypertensives); 5 (6.94%) increased values of passive
Na leak ("Leak +" hypertensives) and 3 (4.16%) exhibited more than
one alteration. Only 5 patients (6.94%) did not show any abnormality in
Na transport systems ("Null" hypertensives). We conclude that the
study of kinetic properties of active Na+ transport systems is useful for
a classification within the heterogeneous population of essential
hypertensives, but not to discriminate the whole population of
hypertensives from the normotensives. Kinetic study allows to define
stable abnormalities not detected in erythrocytes with physiological
Na content but manifested in conditions of Na overload.
Progressively decreasing incidence of membranoproliferative glomeru-
lonephritis in Spanish adult population. A study of 8,545 renal biopsies.
Study Group of the Spanish Society of Nephrology. The annual
incidence of membranoproliferative glomerulonephritis (MPGN) in
adults was analyzed in a retrospective multicenter study which included
33 hospitals, a 17 year period (1970-1986) and 8,545 patients with
primary glomerulonephritis (1405 MPGN). The diagnosis was made on
the basis of renal biopsy (light and immunofluorescence microscopy).
The distribution of MPGN was compared between three periods: Period
I (1970-76, 2,087 patients, 550 MPGN), Period II (1977-81, 3,159
patients, 464 MPGN) and Period III (1982-86, 3,299 patients, 391
MPGN). The incidence of MPGN (26.4%-14.7%-l 1.9% for the three
periods, respectively) was significantly lower for each of the periods
when compared with the preceding period (P < 0.05). This reduced
incidence was observed only in patients with type I MPGN, whereas
the incidence of type II MPGN and its contribution to the total number
of patients with primary glomerulonephritis (I .8%-l .9% and 2% for the
three periods, respectively) did not significantly vary (data from 23
hospitals). When different geographic areas were considered, there
were significant decreases in the Center (3,512 biopsies, 28. l%-16.6%-
10.5%), East (2,636 biopsies, 24.8%-12.5%-l0.6%) and South (770 biop-
sies, 28.3%-16.8%-ll.9%), while in the North of Spain (1,627 biopsies,
l7.2%-13.9%-l5. 1%) there was no significant change during the three
periods. The reasons for the decrease of type I MPGN are not known.
These probably result as much from modifications in immune responsive-
ness as from variations in the incidence of bacterial and viral infections.
Evolution of the incidence of membranoproliferative glomerulonephri-
tis in the Spanish pediatric population. A study of 1,364 renal hiopsies.
Study Group of the Spanish Society of Nephrology. A cooperative
retrospective study was performed in order to establish whether the
incidence of membranoproliferative glomerulonephritis is really de-
creasing in the Spanish pediatric population (under 15 years). Twelve
pediatric nephrology centers (which comprise about 70% of the Spanish
pediatric population) contributed to this study with the results of renal
biopsies performed in primary glomerulonephritis from 1972 to 1986.
All the biopsies had optical and immunofluorescence examination. The
clinicopathological diagnoses were classified as: membranoprohferative
glomerulonephritis (MPGN), Berger disease, membranous GN, mini-
mal change nephrotic syndrome, focal and segmental glomerulosclero-
sis with nephrotic syndrome, diffuse crescentic GN (50%), other GN
and unclassifiable forms. The distinction between types I and II MPGN
was possible in all but one hospital. The total number of valid renal
biopsies included in this study was 1364; 97 of them showed MPGN
(7.11%). They were grouped into 3 five-year periods: I.) 1972-1976 (240
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biopsies); II.) 1977-1982 (571 biopsies), III.) 1982-1986 (553 biopsies).
The incidence of MPGN was significantly lower during period II with
respect to period I: 11.25% vs. 6.83%, P < 0,05, with further stabiliza-
tion during the period III (5.62% NS). We conclude that a significant
decrease of the incidence of MPGN in the Spanish pediatric population
seems to have taken place at the end of the seventies with further
stabilization. There is not a clear explanation for this phenomenon.
Beta2-microglobulin (thM) levels in hemodialysis (HD) patients. Its
variation during RD with different membranes. A. Franco, A. Cabal-
lero, J. Chisvert, J. Luflo, R. Perez, M. Martinez de Merlo, F.
Valderrabano, Hospital U. Maranon, Madrid, Spain. We have studied
the thM predialysis serum levels (RIA) in 76 chronic HD patients who
had been on HD from 0.5 to 13 years (mean 4.7 years). These patients
were treated with different membranes: LID with euprophan (CU) 54
patients, biofiltration with an AN-69 membrane (BF) 17 patients and
hemodiafiltration with polysulphone 5 patients. The serum levels of
thM were high in all cases (mean: 40.5 13.2 mg/liter), but we could
not find a correlation between serum levels of /32M and the previous
time on HD. The mean levels of fl2M in BF patients are significantly
lower than the mean level obtained in patients dialyzed with CU. Ten of
these patients were sequentially submitted to a HD with CU and
AN-69. Serum levels of J32M were obtained in both arterial and venous
lines before HD, and at 15, 60 and 240 minutes. The level of j32M
increases significantly during HD with CU; the maximum level was at
60 mm in the venous line which was significantly higher than the J32M
level obtained in the arterial line. In contrast, fi2M levels decreased
during RD with AN-69 with a maximum decrement at the end of HD
without any differences between the arterial and venous line. At the end
of LID, the mean serum level of with AN-69 was 28.5 13 mg/liter,
significantly lower than the data obtained at the end of the LID with CU:
96 60 mg/liter. In conclusion l3M pre-HD levels are increased in RD
patients. Patients treated with BF have lower levels than patients
dialyzed with CU. During LID, the CU membrane induces a significant
elevation of thM levels, but the AN-69 membrane reduces 2M levels
during dialysis (filtration or adsorption ?).
Determinant factors of beta2-microglobulin (/32m) plasma concentra-
tions during hemodialysis. A. Martin-Malo, J. Mallol, D. Castillo, P.
Andres, E. Andres, R. Perez, P. Alfama, Hospital Regional "Reina
Sofia", Cordoba, Spain. Plasma thm levels are elevated in long-term
hemodiaiysis (HD) patients. Variations have been reported of the
plasma levels of this protein during the course of the HD session
depending on the type of membrane used. The purpose of the present
study was to evaluate the factors which may modify the f32m plasma
concentrations during the HD, such as hemoconcentration, filtration
through the dialyzer and the adsorption capacity of the membrane. The
study was undertaken in ten patients on HD treated in sequence with
euprophan (CU), ethylenevinylalcohol (EVAL), polyacrylonitrile
(AN-69) and polysulphone (PSP) membrane dialyzers. /32m concentra-
tions were measured by radioimmunoassay in plasma and dialysate
samples at 0, 60, 120, 180 and 240 minutes from the start of HD. All
plasma concentrations were corrected for pack red blood cell volume,
We also performed studies of adsorption in vitro by incubating a fixed
amount of the above mentioned membranes with '251-labeled thm.
Plasma: 60' 120' 180' 240'
CU +3.8 +8.4 +12.2b +l3.5"
EVAL —6.1 —1.9 —4.8
AN-69 7,7 —22.9
PSP —17.5
a p c 0.05, b p < 0.01, P < 0.001.
Filtration of thm across the dialysis membrane was absent with CU and
minimal with EVAL (0.4 mg/liter). However, large amounts of f32m
were recovered from dialysates when patients were treated with high
permeability dialyzers AN-69 (0.8 mg/liter) and PSP (2.3 mg/liter). The
in vitro studies demonstrated that the maximal adsorption capacity was
observed with AN-69 (73%); being 9% with CU, 4% with EVAL and 7%
with PSP. CU membrane induced a rise in plasma mm levels whereas
the other membranes tested showed a significant decrease in this
parameter. Plasma fl2m concentration fall was very important with PSP
and AN-69, and minimal with EVAL. The clearance of mm with PSP is
due to a greater removal of this substance by mass transport across the
membrane; whereas the mechanism by which mm is removed from
blood during AN-69 membrane seems to include both absorption and
filtration by the membrane itself.
Deposits of amyloid material (AM) and elevated serum levels of
beta2-microglobulin (thM) in chronic hemodlalysls patients (CHDP).
V.M. Valverde, C. L. Herrero, J.L. Perez, M.A. Soricino, 4. Llopis,
Department of Nephrology, Perpetuo Socorro, Alicante, Spain.
Amyloid material deposition has been accepted as pne of the determi-
nants in the appearance of the carpal tunnel syndrome (CTS) seen in
CHDP. Congophilia, green birefringence to polarized light and sensi-
tivity to KMnO4 are among these AM characteristics, outstanding M
as its main component. A systemic layout has been described, and
among its clinical manifestations there are: CTS, bone lytic lesions
(BLL), recurrent joint effusions (RJE) and pathologic fractures. We
have identified AM deposits in 24 CHDP who underwent a surgical
release of the median nerve because of CTS, in the synovial of 9 with
ME, in 4 with BLL, in tendons or ligaments of S who underwent AVE
reconstruction, and in the stomach of a female aged 51 who was
gastrectomized. Serum thM levels (Enzygnost-M, Behring) were the
same in patients with deposits and in those without them: 82.04 14.4
mg/liter versus 79.12 16.3 mg/liter. Affected patients were on CHD
80.7 months (range 43 to 138), the rest were on CHD 68 months (9 to
146). Age (53.3 vs. 59.1 years), nephropathy and features of CHD
treatment were the same in both groups. All patients had followed CHD
with Cuprophane membrane (Cup). After the surgical release of the
median nerve we made two groups of patients: 15 went on RD with Cup
and 9 were dialysis with high permeability membranes (RPM). In the
first group, 6 patients had a recurrence of CTS (9 to 15 months after
surgery), 9 are asymptomatic (1 to 25 months). In the second group
there is not evidence of recurrence of CTS (5 to 24 months). No
difference in j3M serum levels was found in both groups once reached
6 months of change or maintenance of the membrane: 88.2 16.2
mg/liter with Cup versus 81.17 13.2 mg/liter with RPM. Conclusions:
CHDP have elevated f3M serum levels. AM deposits do not appoar
only in the carpal tunnel area but also in other tissues, and they are
related with CHD time and Cup use (recurrence of CTS in 40% of
patients). RPM avoid recurrence of CTS after 6 months, but serum
levels of M were the same in both groups. The possibility exits that
the null clearance of M by Cup and its accumulation along time could
be a determinant factor in AM deposition, and that the usage of RPM
could avoid this complication which can be determinant in the long run
survival of CHDP.
Visceral involvement of dlalysls-amyloidosis (Am). J.M. Campistol, A.
Torras, J. Mufloz-GOmez, M. Sole, A. cases, J. Montoliu, J. LOpez-
Pedret, L. Revert, Nephrology, Rheumatology and Pathology Depart-
ment, University of Barcelona, Barcelona, Spain. Nineteen patients(pts), (12 males and 7 females) on maintenance hemodialysis with
cuprophan membrane were studied in search of systemic-visceral
amyloid involvement. The mean dialysis time was 10.8 yr (7-16 yr).
None had Am as primary renal disease. Amyloid deposits (AD) were
demonstrated in carpal tunnel structures of 18 pts (95%) and in synovial
fluid or membrane in 17 pts (90%). Subcutaneous abdominal fat
aspiration, rectal biopsy and echocardiogam were performed in most of
the pts. AD were found in: 8 Out of 16 pts in abdominal fat specimen; 4
of 9 in rectal biopsy, but submucous was not presented on the five
negative samples. The echocardiogram showed nodular images in the
interventricular septum suggestive Qf cardiac Am in 7 of 14 pts. AD
were demonstrated in the subendothelium of arterioles and small
arteries of the submucosa and the muscular gastric wall (1 pt); and in the
submucous layer of the colon (1 pt). A necropsy study of one patient
detected the presence of nocular AD on the intestinal submucosa,
heart, liver, lung, testicles, and adrenals glands. Diffuse deposits were
also found in heart, prostate, and perithyroidal tissue. No presence of
AD could be demonstrated in kidney, pancreas, spleen, and central
nervous system. Fourteen of the 19 pts (74%) had AD in extraarticular
structures. AD were resistant to potassium permanganate treatment
and react with antihuman m microglobulin (ABC immunohistochemical
method). We conclude that dialysis-Am has a systemic character and a
visceral involvement.
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Arthropathy in HD. F. Fernández Vega, R. Mann Iranzo, J. Ballina,
E. Gómez, E. Gago, S. Aguado, J. Alvarez Grande, S. de Nefrologla,
Hospital Covadonga, Oviedo, Astunias, Spain. The incidence of
arthropathy in a randomized group of 94 patients (57 M and 37 F)
undergoing periodical hemodialysis (HD), was studied. The mean age
was 53.8 years (range 17-71), the mean time in HD 51.4 months (6-131).
Twenty-nine patients (3 1%) had symptoms and/or signs of arthropathy.
The dialysis duration period and the treatment period with cuprophane
membrane was longer (P < 0.001) than in the group of 65 patients
without arthropathy. No significant differences in age, uricaemia, serum
/32M microglobulin (j3M), CaxP, alkaline phosphatase, PTH and serum
albumin were found. Amyloid deposits were found in the synovial
biopsy of two cases. Septic arthritis was shown in another case. The
etiology could not be determined in the rest. The joint involvement
usually was multiple, above all in hands, wrists and shoulders. In 7
cases (7.5%) carpal tunnel syndrome (CTS) was found. Periarticular
calcifications and erosions were the most common radiologic findings.
No radiologic abnormalities were shown in 6 patients. PTH value was
high in 12 patients (41%) of the arthropathy group. No significant
differences (age, duration in HD, membrane type, CaxP, alkaline
phosphatase, uric acid, aluminum and f32M) were ftund comparing
these 12 patients with the other 17 with PTH normal values. /32M value
of CTS patients group was higher, although not significantly, than that
of the rest of the patients. However, P'FH was significantly raised in this
group (P < 0.01), Thirty-nine patients were maintained more than 5
years in HD. Nineteen (49%) had arthropathy, and 5 (13%) CTS. Of the
other 55 patients maintained less than 5 years, only 10 (18%) had
arthropathy (P < 0.01) and only 2 (3.5%) CTS. Conclusions: 1.) There
is a high incidence of arthropathy in HD. 2.) The existence of
arthropathy is basically related to the duration of HD. 3.) Clinical and
analytical and radiologic findings are inespecific.
Study of sodium erythrocyte homeostasis in essential hypertension.
Relationship to renal sodium excretion. A. Arrázola, L. Yap, J. DIez, R.
DIaz-Tejeiro, F. Maduell, N. Esparza, P. Errasti, A. Purroy, Division
of Nephrology, University Clinic, Pamplona, Spain. Basal Na content
(Na2) and kinetic parameters (maximal velocity and affinity constant
for internal Na+) of outward Na fluxes catalyzed by different trans-
membrane Na+ transport mechanisms were studied in erythrocytes
from 30 healthy subjects without familial history of hypertension (aged
25-56 years; 14 males and 16 females) and 50 essential hypertensive
patients not treated the month previously (aged 17-80; 35 males and 15
females). With respect to the control values, the Na2 was found
elevated in 19 patients (4.56 0.07 vs. 6.50 0.28 mmol/liter celss, M
EEM, P < 0.02). Among these patients, no alteration in the Na
transport mechanisms studied was observed in 11 cases. While in the
remaining 8 cases, the following abnormalities were observed: 3 cases
with diminished Na, K,C1 cotransport activity; 2 cases with low
activity of the Na,K pump; 2 cases with exaggerated Na,Li
countertransport activity and 1 case with increased passive Na
permeability. Patients with elevated Na2 and with alteration in the
Na+ transport demonstrated a fractional Na+ excretion higher than
patients with elevated Na2 but without transport abnormalities (0.75
0.19 vs. 0.28 0.06%, P < 0.02) and higher than patients with normal
Na2 (0.75 0.19 vs. 0.33 0.00%,P < 0.02). No significant difference
was appreciated in the blood pressure among the three groups of
patients. These results suggest that the Na erythrocyte homeostasis is
altered in a subgroup of essential hypertensive patients due to the
existence of heterogeneous abnormalities in the transport mechanisms
which regulate the intracellular Na content. Such abnormalities could
be the molecular markers in the abnormal renal Na+ handling inherent
to established hypertension.
Effect of fenoldopan (F) on renal function in refractory essential
hypertension (RH). B. Miranda, J.M. Alcázar, L.M. Ruilope, R. Garcia
Robles, A. 01/el, J. Sancho, J.L. Rodicio, de Octubre" and
"Ramón y Cajal" Hospitals, Madrid, Spain. The present study was
undertaken in order to assess the effects of intravenous F, a
dopaminergic agonist agent, on blood pressure (BP), heart rate (HR),
inulin (GFR) and PAM (RPF) clearances, fractional excretions of Na
(Fe Na) potassium (Fe K), uric acid (FeUA), calcium (Fe Ca), phos-
phate (Fe P), plasma renin activity (PRA), plasma aldosterone (PA) and
prolactine (PRL). A group of 19 patients diagnosed as having (RH) were
included in the study. F infusion was prolonged during 6 hours, starting
at a dose of 0.05 to 0.01 ng/kg/min augmented every 30 minutes until
DBP fall by 30 mm Hg. The expected fall in BP was obtained in every
case with F doses oscillating between 0.1 and 0.5 ng/kg/min. HR
increased significantly (P < 0.01) and also did GFR and RPF (P < 0.01)
but filtration fraction fell at the same time (P < 0.02) Fe Ca, Fe UA, Fe
P, Fe Na, and Fe K increased accompanying the renal hemodynamic
changes (P < 0.01). Plasma potassium decreased in the third hour
infusion (P < 0.01). PRA, PA & PRL did not suffer any modifications.
These results indicate that in RH, F has important systemic and renal
vasodilatory effects through which blood pressure falls. The increase of
urinary output of uric acid, calcium and phosphate point to a direct
tubular effect of F. The hypotensive action is facilitated by the masked
natriuretic affect of the drug.
Low dose cyclosporine (CyA), ALG and steroids in first cadaveric renal
transplants. f.M. Gninó, A.M. Castelao, I. Sabaté, M. Mestre, S.
Gil-Vernet, E. Andrés, R. Sabater, J. Alsina, Hospital de Bellvitge,
L'Hospitalet de Liobregat, Barcelona, Spain. A randomized trial was
conducted in order to evaluate the benefits of the reduction of initial
CyA doses in the first days after transplant. Two groups of kidney
transplant recipients were prospectively documented. Group A (N
36): CyA 8 mg/kg/day adjusted to RIA whole blood levels (300-600
ng/ml) ALG 10 mg/kg/alternate day to a maximum of 6 doses (after 3
doses, ALG was stopped if CyA blood levels 400 nglml). ALG dosage
modifications in order to maintain peripheral T3 cells between 10-20%;
prednisone (PN) 0.25 mg/kg/day Group B (N = 36) CyA 15 mg/kg/day
adjusted to blood levels (300-800 ng/ml). PN 0.5 mg/kg/day. One year
actuarial graft survival: group A 100%, group B 95%. One year actuarial
patient survival: 100% in both groups. Incidence of postoperative renal
failure: group A 16%, group B 14% (NS); duration of oliguria: group A
4.6 2.4 day, group B 12.2 6 day (NS, P = 0.07). Incidence of acute
rejection during the first 3 months: group A 16%, group B 33% (NS, P
= 0.18) Six months cumulative steroids dose: Group A 2853 962 mg,
group B 3463 687 mg (P = 0.01). Six months cumulative CyA dose:
group A 993 284 mg/kg, group B 1298 491 mg/kg (P = 0.01). At 3
and 6 months serum creatinine and CyA dose were comparable in both
groups. No major infection was observed in any patient. Conclusions.
1.) Low dose CyA, ALG and steroids give similar to results to CyA and
steroids on graft and patient survival. 2.) The triple regimen seems to
reduce the duration of oliguria and the incidence of rejection and
decreases significantly the cumulative doses of steroids and CyA. 3.)
This triple regimen is not associated with opportunistic infections.
Evolution of bone disease in patients with primary hyperoxaluria
(HPO) undergoing chronic hemodialysis (CHD). V. Lorenzo, A. Torres,
D. Hernandez, J. Glez Posada, M. Losada, S. Suria, M. Getino, B.
Maceira, L. Diaz F/ores, Nephrology Unit, University Hospital of
Canary Island, Tenerfe, Spain. PHO is a rare congenital disorder.
Eighty percent of patients with this disease become uremic during the
2nd or 3rd decade of life. Once in hemodialysis the oxalate clearance is
insufficient to prevent tissue deposition and severe cases of bone
oxalosis have been described. We study the evolution of bone disease
in 5 patients (aged 21 to 42 years) with PHO submitted to CHD. Before
hemodialysis therapy was instituted, they remained asymptomatic and
radiological examination of bones and alkaline phosphatase were nor-
mal. The iliac crest undecalcified bone biopsy performed in 2 of 5
patients showed mild hyperosteoidosis, minimal resorption and in one
of them oxalate deposits were observed in peritrabecular areas. After 1
to 3 years in dialysis, 4 of 5 patients developed bone pain. It was severe
in 3 patients who presented radiological signs of osteosclerosis, and
subperiostal resorption, associated to alkaline phosphatase elevation
5-10 times over the normal range, contrasting with PTH plasma levels
hardly elevated. Neither responded to 1,25 (OH)2D3 treatment. The
bone biopsy showed in 5 patients oxalate crystals deposits in bone and
specially in marrow, surrounded by a granulomatous reaction with giant
cells, fibroblasts and marrow fibrosis. The accompanying bone changes
were osteoclastic resorption, excess of woven osteoid with osteoblasts
and fibrosis, associated to an increase of trabecular bone volume (>36%
in 3 patients). Three additional PHO patients with GFR >40 mI/mn
were studied. They showed a normal bone histology and no oxalate
crystal deposits were evidenced at bone. In summary, in PHO the bone
disease develops when advanced uremia occUrs, specially in those who
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receive CHD. The lesions resemble those seen in advanced forms of
secondary hyperparathyroidism and the diagnosis should be confirmed
by bone biopsy, specially when a parathyroidectomy is being consid-
ered.
Predictive value of clinical and biochemical data on the osteomalacic
(OM) form of renal osteodystrophy (RO): Discriminant analysis of 100
cases. A. Torres, D. Hernandez, V. Lorenzo, J.C, Rodriguez, G.
Balaguer, J.M. Gonzalez-Posada, M. Losada, B. Maceira, L.
Hernandez Nieto, Service of Nephrology, University Hospital of Ca-
nary Islands, Tenerife, Spain. The OM form of RO has a multifactorial
origin and its diagnosis is very difficult with the individualized analysis
of clinical and biochemical data. By means of stepwise discriminant
analysis the diagnostic capacity of the group of clinical and biochemical
(Ca, P04, C03H, alk.phosph., PTH-C) data was studied in 100
unselected uremic patients. In all of them an undecalcified iliac crest
bone biopsy was obtained, and static and dynamic (double tetracycline
label) histomorphometric parameters were quantified. 53 had a GFR <
8 mi/mn and were not under dialysis (Pre HD) and 47 were on
hemodialysis for 34 26 mo. OM was equally distributed among
pre-HD (26%) and HD (24%) patients. A positive Al3 stain at the
osteoid/mineralized bone interphase was seen in 21% of pre-HD OM
patients and 36% of HD OM patients. In pre-HD patients the following
criteria were significantly associated to OM and classified correctly:
75% of OM, and 90% of non-OM patients: a) Ca x P04 < 34 mg/dl; b)
interstitial nephropathy as the etiology of renal failure or C03H < 17
mEq/liter (canonic correlation = 0.87; P = 0.002). In the HD group
these criteria were not discriminant for OM. Although PTH correlated
with osteoclasts x mm2 (r = 0.62; P < 0.01) and dialysis duration with
osteoid volume (r = 0.37; P = 0.01) they were not consistent discrimin-
ants for OM in HD patients. In summary, OM seems to have different
causes pre-HD and in HD. In non-dialyzed uremic patients, clinical and
biochemical data have a reasonable diagnostic capacity. This does not
apply to HD patients where the indications of bone biopsy must be
more liberal.
Quadruple therapy In cadaver renal allograft recipients: Alternative
regimen in acute tubular necrosis (ATN). M. Losada, J. M. Glez
Posada, D. Hernandez, S. Suria, A. Torres, V. Lorenzo, M. Getino, Z.
Morales, B. Maceira, Nephrology Unit, Hospital Universitario de
Canarias, Universidad de La Laguna, Tenerfe, Canary Island, Spain.
We retrospectively compared the results at 6 months of 128 cadaver
kidney transplants performed in a Center with a high rate of A1'N (more
than 90%), who were separated in 2 groups according to the im-
munosuppression protocol. Group 1: 85 pts under prednisone (Pred) and
azathioprine (Aza) as maintenance therapy. Group II: 43 pts under
pred, Aza, and prophylactic ATG, switching to Cs A-pred-Aza in the
poliuric phase. Both groups were comparable with respect to age, sex,
diabetic patients, previous time in dialysis, transfusions, HLA-A-B-DR
compatibility/incompatibility and renal preservation times. The rate of
ATN was higher than 90% in both groups. The actuarial, 6 month
patient-survival-rate in groups I and II were 95% and 93%, respectively,
with corresponding graft survival rate of 72.9% and 88.4% (P 0.05).
In the same period the number of rejections, accumulated 6-
M-prednisolone and the hospitalization time were significantly lower in
group II (P <0.0001, P <0.0001, P = 0.01 respectively). Eleven second
transplant and 5 pts with historical-positive/actual-negative cross-match
were all included in group II. No significant differences were found in
the number of sepsis, pneumonias, urinary tract infections, steroid
induced diabetes, upper 01 bleeding or CMV infection. There were 3
pts with pneumocystis carinii pneumonia in group II. We concluded
that sequential immunosuppression with ATG-CsA plus pred and Aza
may offer advantages in cadaver kidney transplants preventing CsA
nephrotoxicity in the early posttransplant period, improving the graft
survival, with a low frequency of complications.
